


Contents

| | |
|--|----|
| Figures | 3 |
| Figure A1: Directed acyclic graph (DAG) illustrating implicitly assumed causal structure between household exposure to children and recorded SARS-CoV-2 infection, and severe outcomes from COVID-19 | 3 |
| Figure A2: Flow diagram of cohort with numbers excluded at different stages for wave 1 and wave 2..... | 4 |
| Figure A3: Histograms of frequencies of outcomes (recorded SARS-CoV-2 infection, COVID-19 outcomes and non-COVID-19 deaths) in wave 1 (1st February to 31st August 2020) and wave 2 (1st September to 18th December)..... | 5 |
| Figure A4: Adjusted* Hazard Ratios (HRs) for outcomes ((a) recorded SARS-CoV-2 infection, (b) COVID-19 hospital admission, (c) COVID-19 ICU admission, (d) COVID-19 death and (e) non-COVID-19 death) among adults aged >65 years, for waves 1 and 2 of the UK pandemic... 6 | 6 |
| Figure A5. Comorbidity adjusted hazard ratios (HRs) and 95% confidence intervals (CI) for each COVID-19 outcome in wave 1 and wave 2, compared to having no children in the household by (a) sex, (b) shielding status among those >65 years. | 7 |
| Figure A6: Results from sensitivity analysis: Hazard Ratios (HRs) for each COVID-19 outcome (a) evidence of SARS-CoV-2 infection recorded in primary care, (b) COVID-19 hospital admission, (c) COVID-19 ICU admission and (d) COVID-19 death), among those ≤65 years 9 | 9 |
| Figure A7: Results from sensitivity analysis creating alternative exposure definition which identifies children aged 0-4 years: Hazard Ratios (HRs) for each COVID-19 outcome (a) among those ≤65 years (b) among those >65 years | 13 |
| Tables..... | 15 |
| Table A1: Changes to the original study protocol | 15 |
| Table A2. Cohort description, of adults >65 years, by presence of children in the household during Wave 1 and Wave 2 of the pandemic | 17 |
| Table A3. Cohort description by outcomes (evidence of SARS-CoV-2 infection recorded in primary care, COVID-19 outcomes and non-COVID 19 deaths) for adults ≤65 years in wave 1 and wave 2 of the UK pandemic..... | 22 |
| Table A4. Source of diagnoses for the outcome of SARS-CoV-2 infection by wave and exposure status..... | 26 |
| Table A5. Cohort description by outcomes (evidence of SARS-CoV-2 infection recorded in primary care, COVID-19 outcomes and non-COVID 19 deaths) for adults >65 years in wave 1 and wave 2 of the UK pandemic | 27 |
| Table A6. Hazard Ratios (HRs) for outcomes in wave 1 and wave 2 (a) evidence of SARS-CoV-2 infection recorded in primary care, (b) COVID-19 hospital admission, (c) COVID-19 ICU admission, (d) COVID-19 death and (e) non-COVID-19 death), stratified by age. | 32 |
| Table A7. Hazard Ratios (HRs) for threadworm between 2018 to 2019, stratified by age | 37 |

| | |
|--|----|
| Table A8: Hazard Ratios (HRs) and 95% confidence intervals (CIs) for COVID-19 outcomes among those ≤ 65 years, comparing results of complete case analysis with multiple imputation to account for ethnicity. | 38 |
| Table A9: Hazard Ratios (HRs) and 95% confidence intervals (CIs) for COVID-19 outcomes among those >65 years, comparing results of complete case analysis with multiple imputation to account for ethnicity | 39 |
| Table A10: Bias-adjusted hazard ratios accounting for high-risk occupation for the association between living in a household with children and Covid-19 outcome among adults aged ≤ 65 years assuming a hazard ratio between high-risk occupation and outcome of 1.3..... | 40 |
| Table A11: Bias-adjusted hazard ratios accounting for high-risk occupation for the association between living in a household with children and Covid-19 outcomes among adults aged ≤ 65 years assuming a hazard ratio between high-risk occupation and outcome of 2..... | 41 |
| Table A12: Bias-adjusted hazard ratios accounting for high-risk occupation for the association between living in a household with children and Covid-19 outcomes among adults aged ≤ 65 years assuming a hazard ratio between high-risk occupation and outcome of 3..... | 42 |
| Supplementary methods..... | 43 |
| Algorithm to identify households in TPP, using addresses registered in patient record..... | 43 |
| Table of primary care codes used as evidence of SARS-CoV-2 infection in primary care with links to codelists | 44 |
| Table of covariate definitions | 44 |
| Table of chronic comorbidities with details and links to codelists | 45 |
| Further details of quantitative bias analysis..... | 48 |

Figures

Figure A1: Directed acyclic graph (DAG) illustrating implicitly assumed causal structure between household exposure to children and recorded SARS-CoV-2 infection, and severe outcomes from COVID-19



Explanatory note: Variables that could confound the relationship between household exposure to children and COVID-19 outcomes were identified using a directed acyclic graph. Both expert opinion and current literature were used to identify plausible confounders and to specify known causal paths. We can infer from the graph that we can estimate the total effect of household exposure to children on the risk of COVID-19 outcomes by adjusting for age, BMI, chronic comorbidities, deprivation, ethnicity, high-risk occupation, number adults in household and sex. Although we weren't able to adjust for high-risk occupation, we sought to consider the potential impact of this in the quantitative bias analysis.

Figure A2: Flow diagram of cohort with numbers excluded at different stages for wave 1 and wave 2





Figure A3: Histograms of frequencies of outcomes (recorded SARS-CoV-2 infection, COVID-19 outcomes and non-COVID-19 deaths) in wave 1 (1st February to 31st August 2020) and wave 2 (1st September to 18th December).

Wave 1



Wave 2




Figure A4: Adjusted* Hazard Ratios (HRs) for outcomes ((a) recorded SARS-CoV-2 infection, (b) COVID-19 hospital admission, (c) COVID-19 ICU admission, (d) COVID-19 death and (e) non-COVID-19 death) among adults aged >65 years, for waves 1 and 2 of the UK pandemic.






Figure A5. Comorbidity adjusted hazard ratios (HRs) and 95% confidence intervals (CI) for each COVID-19 outcome in wave 1 and wave 2, compared to having no children in the household by (a) sex, (b) shielding status among those >65 years.

a) Sex

Wave 1




Wave 2



b) Shielding status

Wave 1



Wave 2






Figure A6: Results from sensitivity analysis: Hazard Ratios (HRs) for each COVID-19 outcome (a) evidence of SARS-CoV-2 infection recorded in primary care, (b) COVID-19 hospital admission, (c) COVID-19 ICU admission and (d) COVID-19 death), among those ≤65 years
(a) Recorded SARS-CoV-2 infection

Wave 1




Wave 2




(b) COVID-19 hospital admission

Wave 1




Wave 2




(c) COVID-19 ICU admission

Wave 1




Wave 2



(d) COVID-19 death

Wave 1



Wave 2






Figure A7: Results from sensitivity analysis creating alternative exposure definition which identifies children aged 0-4 years: Hazard Ratios (HRs) for each COVID-19 outcome (a) among those ≤ 65 years (b) among those >65 years

a) Age ≤ 65 years



b) Age >65 years



Tables

Table A1: Changes to the original study protocol

| Suggestion | Rationale |
|--|--|
| Stratify all results on age above and below 65 years. | We were concerned that our age adjustment was not sufficient to capture the variation in risk of infection with SARS-CoV-2 among those working and after retirement. |
| Extract a second cohort to explore association in wave 2 | We added an additional analysis to explore the association during wave 2 (September 1st to December 18th). |
| Revised exposure definition | We have revised the exposure group as follows: No children; only children 0-11 years; only children 12-18 years; both children 0-11 years and 12-18 years. |
| Revised SARS-CoV-2 definition | Given the marked increases in testing and improved data flows since study inception we have added SGSS test data in addition to primary care codes to define infection with SARS-CoV-2, increasing our ascertainment of infection. (SGSS is Public Health England’s “Second Generation Surveillance System” in which SARS-CoV-2 PCR tests are recorded). |
| Add sensitivity analysis to assess risk of COVID-19 outcomes among adults living with nursery school aged children. | In light of current English (but not Scottish) Government policy around nurseries remaining open we included an additional analysis splitting the “only children 0 to 11 years” group into 0-4 (pre-school) and 5-11 years (primary school) aged children. |
| Separate COVID death and ICU admission | In early analyses the effect of living with children was in different directions for death from COVID-19 and ICU admission with COVID-19. In addition we had confirmed that there was adequate power to model each outcome separately. |
| Add non-COVID 19 death as an outcome | To contextualise our findings by comparing the risk of death from COVID-19 to and other causes. |
| Adjust for number of adults in household, rather than total number of people in the household | Data exploration showed that most of the additional people in a household were children, so results would have been hard to interpret if the ‘dose-response’ effect was also incorporated in the main model |
| Drop the planned sensitivity analysis using an alternative definition of COVID-19 in primary care to include diagnostic codes for suspected cases. | Exploration of suspected COVID-19 cases in primary care suggested there could be substantial misclassification of this outcome |

| | |
|---|---|
| Add outcome hospital admission for COVID-19 | This outcome became available during the time course of the study, and it enabled us to examine whether the findings were consistent with those for ICU admission |
| Re-run analysis with age as the underlying timescale, as a sensitivity analysis | To confirm we are adequately adjusting for age. |
| Developing a directed-acyclic graph to inform our model covariates | To confirm we are adjusting for all appropriate variables and not introducing collider bias. |
| Additional model fitting a time-interaction with variables where there was evidence of non-proportional hazards | To examine whether introducing time interactions where there was evidence of non-proportional hazards materially altered our findings. |
| Use multiple imputation to impute missing data for ethnicity | To examine whether the reduced study population introduced by adjusting for ethnicity altered our results in a meaningful way. |

Table A2. Cohort description, of adults >65 years, by presence of children in the household during Wave 1 and Wave 2 of the pandemic

| | Wave 1 (1st February - 31st August) | | | | | Wave 2 (1st September - 18th December) | | | | |
|-------------------------|-------------------------------------|--------------------------------------|-------------------------------|---------------------------------|--|--|--------------------------------------|-------------------------------|--------------------------------|--|
| | | Children in the household (column %) | | | | | Children in the household (column %) | | | |
| | Total cohort, n (%) | No children | Only children aged 0-11 years | Only children aged 12 -18 years | Children aged 0-11 and children aged 12-18 years | Total cohort, n (%) | No children | Only children aged 0-11 years | Only children aged 12-18 years | Children aged 0-11 and children aged 12-18 years |
| Total | 2684524 (100.0) | 2595472 (100.00) | 44420 (100.00) | 29227 (100.00) | 15405 (100.00) | 2706505 (100.0) | 2616423 (100.00) | 44335 (100.00) | 29854 (100.00) | 15893 (100.00) |
| Age | | | | | | | | | | |
| >65-70 | 633913 (23.6) | 601603 (23.18) | 17863 (40.21) | 9030 (30.90) | 5417 (35.16) | 632027 (23.4) | 599415 (22.91) | 17826 (40.21) | 9162 (30.69) | 5624 (35.39) |
| 70-80 | 1357522 (50.6) | 1314301 (50.64) | 20952 (47.17) | 14752 (50.47) | 7517 (48.80) | 1375657 (50.8) | 1331707 (50.90) | 21017 (47.40) | 15153 (50.76) | 7780 (48.95) |
| 80+ | 693089 (25.8) | 679568 (26.18) | 5605 (12.62) | 5445 (18.63) | 2471 (16.04) | 698821 (25.8) | 685301 (26.19) | 5492 (12.39) | 5539 (18.55) | 2489 (15.66) |
| Sex | | | | | | | | | | |
| Female | 1445097 (53.8) | 1397650 (53.85) | 23411 (52.70) | 15309 (52.38) | 8727 (56.65) | 1457578 (53.9) | 1409510 (53.87) | 23386 (52.75) | 15668 (52.48) | 9014 (56.72) |
| Male | 1239427 (46.2) | 1197822 (46.15) | 21009 (47.30) | 13918 (47.62) | 6678 (43.35) | 1248927 (46.1) | 1206913 (46.13) | 20949 (47.25) | 14186 (47.52) | 6879 (43.28) |
| BMI (kg/m2) | | | | | | | | | | |
| <18.5 | 48518 (1.8) | 47232 (1.82) | 596 (1.34) | 465 (1.59) | 225 (1.46) | 44591 (1.6) | 43371 (1.66) | 551 (1.24) | 438 (1.47) | 231 (1.45) |
| 18.5-24.9 | 800412 (29.8) | 777844 (29.97) | 11709 (26.36) | 7168 (24.53) | 3691 (23.96) | 793996 (29.3) | 771543 (29.49) | 11437 (25.80) | 7215 (24.17) | 3801 (23.92) |
| 25-29.9 | 987076 (36.8) | 955538 (36.82) | 15690 (35.32) | 10585 (36.22) | 5263 (34.16) | 994595 (36.7) | 962848 (36.80) | 15609 (35.21) | 10703 (35.85) | 5435 (34.20) |
| 30-34.9 (Obese class I) | 479258 (17.9) | 461889 (17.80) | 8560 (19.27) | 5693 (19.48) | 3116 (20.23) | 485856 (18.0) | 468212 (17.90) | 8545 (19.27) | 5891 (19.73) | 3208 (20.18) |
| 35-39.9 (Obese | 156751 (5.8) | 150696 (5.81) | 2877 (6.48) | 2073 (7.09) | 1105 (7.17) | 159518 (5.9) | 153406 (5.86) | 2893 (6.53) | 2095 (7.02) | 1124 (7.07) |

| | | | | | | | | | | |
|---|----------------|-----------------|---------------|---------------|--------------|----------------|-----------------|---------------|---------------|--------------|
| class II) | | | | | | | | | | |
| ≥40 (Obese class III) | 61135 (2.3) | 58530 (2.26) | 1227 (2.76) | 875 (2.99) | 503 (3.27) | 62493 (2.3) | 59863 (2.29) | 1235 (2.79) | 902 (3.02) | 493 (3.10) |
| <i>Missing</i> | 151374 (5.6) | 143743 (5.54) | 3761 (8.47) | 2368 (8.10) | 1502 (9.75) | 165456 (6.1) | 157180 (6.01) | 4065 (9.17) | 2610 (8.74) | 1601 (10.07) |
| Smoking | | | | | | | | | | |
| Never | 1060734 (39.5) | 1017749 (39.21) | 21672 (48.79) | 13150 (44.99) | 8163 (52.99) | 1073743 (39.7) | 1030164 (39.37) | 21685 (48.91) | 13480 (45.15) | 8414 (52.94) |
| Former | 1395189 (52.0) | 1359139 (52.37) | 17673 (39.79) | 12873 (44.04) | 5504 (35.73) | 1404161 (51.9) | 1367878 (52.28) | 17551 (39.59) | 13095 (43.86) | 5637 (35.47) |
| Current | 222197 (8.3) | 213161 (8.21) | 4554 (10.25) | 2974 (10.18) | 1508 (9.79) | 222251 (8.2) | 213027 (8.14) | 4593 (10.36) | 3036 (10.17) | 1595 (10.04) |
| <i>Missing</i> | 6404 (0.2) | 5423 (0.21) | 521 (1.17) | 230 (0.79) | 230 (1.49) | 6350 (0.2) | 5354 (0.20) | 506 (1.14) | 243 (0.81) | 247 (1.55) |
| Ethnicity | | | | | | | | | | |
| White | 2533944 (94.4) | 2475149 (95.36) | 28867 (64.99) | 21381 (73.15) | 8547 (55.48) | 2552971 (94.3) | 2493459 (95.30) | 28815 (64.99) | 21851 (73.19) | 8846 (55.66) |
| Mixed | 9970 (0.4) | 8847 (0.34) | 542 (1.22) | 371 (1.27) | 210 (1.36) | 10249 (0.4) | 9122 (0.35) | 549 (1.24) | 361 (1.21) | 217 (1.37) |
| South Asian | 91000 (3.4) | 68550 (2.64) | 11626 (26.17) | 5525 (18.90) | 5299 (34.40) | 92732 (3.4) | 70126 (2.68) | 11582 (26.12) | 5618 (18.82) | 5406 (34.01) |
| Black | 27818 (1.0) | 24091 (0.93) | 1761 (3.96) | 1159 (3.97) | 807 (5.24) | 28209 (1.0) | 24402 (0.93) | 1771 (3.99) | 1227 (4.11) | 809 (5.09) |
| Other | 21792 (0.8) | 18835 (0.73) | 1624 (3.66) | 791 (2.71) | 542 (3.52) | 22344 (0.8) | 19314 (0.74) | 1618 (3.65) | 797 (2.67) | 615 (3.87) |
| IMD quintile | | | | | | | | | | |
| 1 (least deprived) | 651069 (24.3) | 635133 (24.47) | 7829 (17.62) | 5705 (19.52) | 2402 (15.59) | 668867 (24.7) | 652542 (24.94) | 7945 (17.92) | 5868 (19.66) | 2512 (15.81) |
| 2 | 629037 (23.4) | 612217 (23.59) | 8482 (19.10) | 5656 (19.35) | 2682 (17.41) | 636250 (23.5) | 619228 (23.67) | 8386 (18.92) | 5888 (19.72) | 2748 (17.29) |
| 3 | 580534 (21.6) | 561800 (21.65) | 9483 (21.35) | 6272 (21.46) | 2979 (19.34) | 574847 (21.2) | 556103 (21.25) | 9309 (21.00) | 6331 (21.21) | 3104 (19.53) |
| 4 | 477447 (17.8) | 457663 (17.63) | 9876 (22.23) | 6212 (21.25) | 3696 (23.99) | 479967 (17.7) | 459987 (17.58) | 9980 (22.51) | 6246 (20.92) | 3754 (23.62) |
| 5 (most deprived) | 346437 (12.9) | 328659 (12.66) | 8750 (19.70) | 5382 (18.41) | 3646 (23.67) | 346574 (12.8) | 328563 (12.56) | 8715 (19.66) | 5521 (18.49) | 3775 (23.75) |
| Total number adults in household | | | | | | | | | | |

| | | | | | | | | | | |
|--|----------------|-----------------|---------------|---------------|---------------|----------------|-----------------|---------------|---------------|---------------|
| 1 | 913998 (34.0) | 910750 (35.09) | 1435 (3.23) | 1549 (5.30) | 264 (1.71) | 921594 (34.1) | 918322 (35.10) | 1432 (3.23) | 1579 (5.29) | 261 (1.64) |
| 2 | 1384390 (51.6) | 1367469 (52.69) | 7590 (17.09) | 7295 (24.96) | 2036 (13.22) | 1390726 (51.4) | 1373830 (52.51) | 7533 (16.99) | 7296 (24.44) | 2067 (13.01) |
| ≥3 | 386136 (14.4) | 317253 (12.22) | 35395 (79.68) | 20383 (69.74) | 13105 (85.07) | 394185 (14.6) | 324271 (12.39) | 35370 (79.78) | 20979 (70.27) | 13565 (85.35) |
| Blood pressure | | | | | | | | | | |
| Normal | 309796 (11.5) | 298880 (11.52) | 5551 (12.50) | 3457 (11.83) | 1908 (12.39) | 310503 (11.5) | 299723 (11.46) | 5394 (12.17) | 3510 (11.76) | 1876 (11.80) |
| Elevated | 417855 (15.6) | 404259 (15.58) | 6827 (15.37) | 4429 (15.15) | 2340 (15.19) | 422947 (15.6) | 409265 (15.64) | 6749 (15.22) | 4496 (15.06) | 2437 (15.33) |
| High Stage 1 | 990139 (36.9) | 957771 (36.90) | 16184 (36.43) | 10608 (36.30) | 5576 (36.20) | 1011992 (37.4) | 978709 (37.41) | 16518 (37.26) | 10989 (36.81) | 5776 (36.34) |
| High Stage 2 | 952842 (35.5) | 923056 (35.56) | 14516 (32.68) | 10192 (34.87) | 5078 (32.96) | 946777 (35.0) | 916919 (35.04) | 14329 (32.32) | 10281 (34.44) | 5248 (33.02) |
| Missing | 13892 (0.5) | 11506 (0.44) | 1342 (3.02) | 541 (1.85) | 503 (3.27) | 14286 (0.5) | 11807 (0.45) | 1345 (3.03) | 578 (1.94) | 556 (3.50) |
| High bp or diagnosed hypertension | 1859250 (69.3) | 1799565 (69.33) | 29235 (65.81) | 20126 (68.86) | 10324 (67.02) | 1858019 (68.7) | 1798291 (68.73) | 28917 (65.22) | 20336 (68.12) | 10475 (65.91) |
| Comorbidities | | | | | | | | | | |
| Chronic respiratory disease ex asthma | 334940 (12.5) | 324968 (12.52) | 4769 (10.74) | 3627 (12.41) | 1576 (10.23) | 324691 (12.0) | 315049 (12.04) | 4507 (10.17) | 3563 (11.93) | 1572 (9.89) |
| Asthma | 362235 (13.5) | 349399 (13.46) | 6392 (14.39) | 4190 (14.34) | 2254 (14.63) | 366433 (13.5) | 353571 (13.51) | 6353 (14.33) | 4202 (14.08) | 2307 (14.52) |
| Chronic cardiac disease | 571371 (21.3) | 553202 (21.31) | 8687 (19.56) | 6283 (21.50) | 3199 (20.77) | 551840 (20.4) | 534326 (20.42) | 8245 (18.60) | 6174 (20.68) | 3095 (19.47) |
| Diabetes | | | | | | | | | | |
| No diabetes | 2201205 (82.0) | 2135805 (82.29) | 32686 (73.58) | 21947 (75.09) | 10767 (69.89) | 2221833 (82.1) | 2155520 (82.38) | 32726 (73.82) | 22454 (75.21) | 11133 (70.05) |
| Type 1, controlled | 3563 (0.1) | 3463 (0.13) | 48 (0.11) | 36 (0.12) | 16 (0.10) | 3710 (0.1) | 3609 (0.14) | 48 (0.11) | 37 (0.12) | 16 (0.10) |
| Type 1, uncontrolled | 7408 (0.3) | 7191 (0.28) | 98 (0.22) | 80 (0.27) | 39 (0.25) | 7352 (0.3) | 7137 (0.27) | 104 (0.23) | 74 (0.25) | 37 (0.23) |
| Type 2, controlled | 323854 (12.1) | 309255 (11.92) | 7246 (16.31) | 4578 (15.66) | 2775 (18.01) | 323947 (12.0) | 309264 (11.82) | 7154 (16.14) | 4691 (15.71) | 2838 (17.86) |
| Type 2, | 146537 (5.5) | 137999 (5.32) | 4251 (9.57) | 2530 (8.66) | 1757 (11.41) | 147893 (5.5) | 139316 (5.32) | 4196 (9.46) | 2552 (8.55) | 1829 (11.51) |

| | | | | | | | | | | |
|----------------------------------|---------------|----------------|--------------|--------------|--------------|---------------|----------------|--------------|--------------|--------------|
| uncontrolled | | | | | | | | | | |
| Diabetes, no HbA1c | 1957 (0.1) | 1759 (0.07) | 91 (0.20) | 56 (0.19) | 51 (0.33) | 1770 (0.1) | 1577 (0.06) | 107 (0.24) | 46 (0.15) | 40 (0.25) |
| Haematological cancer | | | | | | | | | | |
| Diagnosed < 1 year ago | 3839 (0.1) | 3735 (0.14) | 48 (0.11) | 39 (0.13) | 17 (0.11) | 3499 (0.1) | 3410 (0.13) | 36 (0.08) | 35 (0.12) | 18 (0.11) |
| Diagnosed 1-4.9 years ago | 11638 (0.4) | 11326 (0.44) | 149 (0.34) | 113 (0.39) | 50 (0.32) | 11138 (0.4) | 10848 (0.41) | 134 (0.30) | 113 (0.38) | 43 (0.27) |
| Diagnosed ≥5 years ago | 23786 (0.9) | 23176 (0.89) | 295 (0.66) | 205 (0.70) | 110 (0.71) | 23008 (0.9) | 22415 (0.86) | 286 (0.65) | 202 (0.68) | 105 (0.66) |
| Non-haematological cancer | | | | | | | | | | |
| Diagnosed < 1 year ago | 32334 (1.2) | 31478 (1.21) | 447 (1.01) | 282 (0.96) | 127 (0.82) | 29009 (1.1) | 28240 (1.08) | 399 (0.90) | 249 (0.83) | 121 (0.76) |
| Diagnosed 1-4.9 years ago | 95696 (3.6) | 93208 (3.59) | 1211 (2.73) | 850 (2.91) | 427 (2.77) | 92748 (3.4) | 90331 (3.45) | 1191 (2.69) | 819 (2.74) | 407 (2.56) |
| Diagnosed ≥5 years ago | 254667 (9.5) | 249106 (9.60) | 2670 (6.01) | 2066 (7.07) | 825 (5.36) | 248878 (9.2) | 243450 (9.30) | 2565 (5.79) | 2060 (6.90) | 803 (5.05) |
| Reduced kidney function | | | | | | | | | | |
| Estimated GFR 30-60 | 563148 (21.0) | 548113 (21.12) | 6880 (15.49) | 5454 (18.66) | 2701 (17.53) | 560736 (20.7) | 545878 (20.86) | 6720 (15.16) | 5474 (18.34) | 2664 (16.76) |
| Estimated GFR <30 | 41148 (1.5) | 39702 (1.53) | 668 (1.50) | 485 (1.66) | 293 (1.90) | 40212 (1.5) | 38848 (1.48) | 612 (1.38) | 471 (1.58) | 281 (1.77) |
| End-stage renal disease* | 6885 (0.3) | 6498 (0.25) | 183 (0.41) | 117 (0.40) | 87 (0.56) | 6285 (0.2) | 5934 (0.23) | 159 (0.36) | 110 (0.37) | 82 (0.52) |
| Chronic Liver disease | 26389 (1.0) | 25427 (0.98) | 456 (1.03) | 316 (1.08) | 190 (1.23) | 25834 (1.0) | 24900 (0.95) | 426 (0.96) | 319 (1.07) | 189 (1.19) |
| Stroke/dementia | 204093 (7.6) | 198024 (7.63) | 2868 (6.46) | 2095 (7.17) | 1106 (7.18) | 191057 (7.1) | 185318 (7.08) | 2676 (6.04) | 2016 (6.75) | 1047 (6.59) |

| | | | | | | | | | | |
|--|----------------|-----------------|---------------|---------------|--------------|----------------|-----------------|---------------|---------------|--------------|
| Other neurological disease | 54121 (2.0) | 52516 (2.02) | 775 (1.74) | 528 (1.81) | 302 (1.96) | 51397 (1.9) | 49856 (1.91) | 719 (1.62) | 534 (1.79) | 288 (1.81) |
| Solid organ transplant** | 872 (0.0) | 821 (0.03) | 22 (0.05) | 17 (0.06) | 12 (0.08) | 852 (0.0) | 802 (0.03) | 19 (0.04) | 17 (0.06) | 14 (0.09) |
| Asplenia | 6733 (0.3) | 6556 (0.25) | 79 (0.18) | 70 (0.24) | 28 (0.18) | 6639 (0.2) | 6458 (0.25) | 88 (0.20) | 67 (0.22) | 26 (0.16) |
| Rheumatoid/Lupus / Psoriasis | 208673 (7.8) | 202704 (7.81) | 2951 (6.64) | 2096 (7.17) | 922 (5.99) | 208797 (7.7) | 202856 (7.75) | 2917 (6.58) | 2061 (6.90) | 963 (6.06) |
| Other immunosuppressive condition | 5397 (0.2) | 5192 (0.20) | 99 (0.22) | 70 (0.24) | 36 (0.23) | 5658 (0.2) | 5448 (0.21) | 110 (0.25) | 68 (0.23) | 32 (0.20) |
| Probable shielding*** | 956589 (35.6) | 928407 (35.77) | 13753 (30.96) | 9756 (33.38) | 4673 (30.33) | 941453 (34.8) | 913752 (34.92) | 13374 (30.17) | 9663 (32.37) | 4664 (29.35) |
| Any comorbidity**** | 1638898 (61.0) | 1584706 (61.06) | 26541 (59.75) | 18171 (62.17) | 9480 (61.54) | 1623911 (60.0) | 1570025 (60.01) | 26049 (58.75) | 18226 (61.05) | 9611 (60.47) |

*End-stage renal disease includes on dialysis or having had a kidney transplant

**All solid organ transplants, excluding kidney

***Shielding includes organ transplant recipients, renal replacement therapy, haematological cancers, non-haematological cancers, immunodeficiencies/asplenia and severe respiratory conditions.

****Any comorbidity includes: chronic respiratory disease, asthma, chronic cardiac disease, diabetes, cancer, end-stage renal disease, chronic liver disease, stroke or dementia, other neurological disease, other transplant, asplenia, Rheumatoid/Lupus/ Psoriasis or other immunosuppressive condition

Table A3. Cohort description by outcomes (evidence of SARS-CoV-2 infection recorded in primary care, COVID-19 outcomes and non-COVID 19 deaths) for adults ≤65 years in wave 1 and wave 2 of the UK pandemic

| | Wave 1 (1st February to 31st August 2020) | | | | | | Wave 2 (1st February to 31st August 2020) | | | | | |
|--------------------------|---|-------------------------------|------------------------------|-------------------------|-----------------|---------------------|---|-------------------------------|------------------------------|-------------------------|-----------------|---------------------|
| | | Number (%) within stratum | | | | | | Number (%) within stratum | | | | |
| | N (column %) | Recorded SARS-CoV-2 infection | COVID-19 hospital admissions | COVID-19 ICU admissions | COVID-19 deaths | Non-COVID-19 deaths | N (column %) | Recorded SARS-CoV-2 infection | COVID-19 hospital admissions | COVID-19 ICU admissions | COVID-19 deaths | Non-COVID-19 deaths |
| Total | 9334392 (100.0) | 51560 (0.55) | 6374 (0.07) | 1601 (0.02) | 1219 (0.01) | 10580 (0.11) | 9266919 (100.0) | 241693 (2.61) | 3616 (0.04) | 1102 (0.01) | 591 (0.01) | 4409 (0.05) |
| Age | | | | | | | | | | | | |
| 18-<30 | 1981860 (21.2) | 9778 (0.49) | 345 (0.02) | 45 (0.00) | 12 (0.00) | 280 (0.01) | 1912652 (20.6) | 62523 (3.27) | 246 (0.01) | 39 (0.00) | 6 (0.00) | 60 (0.00) |
| 30-<40 | 2230655 (23.9) | 11580 (0.52) | 766 (0.03) | 132 (0.01) | 46 (0.00) | 654 (0.03) | 2222046 (24.0) | 56007 (2.52) | 440 (0.02) | 102 (0.00) | 14 (0.00) | 205 (0.01) |
| 40-<50 | 2022059 (21.7) | 11897 (0.59) | 1402 (0.07) | 316 (0.02) | 160 (0.01) | 1671 (0.08) | 2021030 (21.8) | 52553 (2.60) | 771 (0.04) | 222 (0.01) | 67 (0.00) | 647 (0.03) |
| 50-<60 | 2062371 (22.1) | 12740 (0.62) | 2344 (0.11) | 648 (0.03) | 466 (0.02) | 4001 (0.19) | 2064172 (22.3) | 51315 (2.49) | 1302 (0.06) | 426 (0.02) | 250 (0.01) | 1772 (0.09) |
| 60-<66 | 1037447 (11.1) | 5565 (0.54) | 1517 (0.15) | 460 (0.04) | 535 (0.05) | 3974 (0.38) | 1047019 (11.3) | 19295 (1.84) | 857 (0.08) | 313 (0.03) | 254 (0.02) | 1725 (0.16) |
| Sex | | | | | | | | | | | | |
| Female | 4802386 (51.4) | 30629 (0.64) | 2740 (0.06) | 513 (0.01) | 436 (0.01) | 4284 (0.09) | 4757515 (51.3) | 135947 (2.86) | 1573 (0.03) | 342 (0.01) | 201 (0.00) | 1866 (0.04) |
| Male | 4532006 (48.6) | 20931 (0.46) | 3634 (0.08) | 1088 (0.02) | 783 (0.02) | 6296 (0.14) | 4509404 (48.7) | 105746 (2.35) | 2043 (0.05) | 760 (0.02) | 390 (0.01) | 2543 (0.06) |
| BMI (kg/m2) | | | | | | | | | | | | |
| <18.5 | 180395 (1.9) | 804 (0.45) | 74 (0.04) | 9 (0.00) | 22 (0.01) | 579 (0.32) | 177343 (1.9) | 3515 (1.98) | 31 (0.02) | 5 (0.00) | 11 (0.01) | 230 (0.13) |
| 18.5-24.9 | 2886762 (30.9) | 13498 (0.47) | 981 (0.03) | 184 (0.01) | 194 (0.01) | 3170 (0.11) | 2822640 (30.5) | 66149 (2.34) | 442 (0.02) | 97 (0.00) | 74 (0.00) | 1286 (0.05) |
| 25-29.9 | 2551873 (27.3) | 14743 (0.58) | 1829 (0.07) | 434 (0.02) | 319 (0.01) | 2714 (0.11) | 2489283 (26.9) | 67124 (2.70) | 944 (0.04) | 248 (0.01) | 131 (0.01) | 1107 (0.04) |
| 30-34.9 (Obese class I) | 1286837 (13.8) | 9118 (0.71) | 1470 (0.11) | 414 (0.03) | 251 (0.02) | 1610 (0.13) | 1256346 (13.6) | 38047 (3.03) | 890 (0.07) | 314 (0.02) | 154 (0.01) | 710 (0.06) |
| 35-39.9 (Obese class II) | 521821 (5.6) | 4207 (0.81) | 824 (0.16) | 232 (0.04) | 180 (0.03) | 737 (0.14) | 510314 (5.5) | 16402 (3.21) | 518 (0.10) | 169 (0.03) | 87 (0.02) | 339 (0.07) |
| ≥40 (Obese class III) | 281814 (3.0) | 2655 (0.94) | 601 (0.21) | 170 (0.06) | 123 (0.04) | 584 (0.21) | 275736 (3.0) | 9298 (3.37) | 397 (0.14) | 142 (0.05) | 71 (0.03) | 233 (0.08) |
| <i>Missing</i> | 1624890 (17.4) | 6535 (0.40) | 595 (0.04) | 158 (0.01) | 130 (0.01) | 1186 (0.07) | 1735257 (18.7) | 41158 (2.37) | 394 (0.02) | 127 (0.01) | 63 (0.00) | 504 (0.03) |

| | | | | | | | | | | | | |
|---|----------------|--------------|-------------|-------------|------------|-------------|----------------|---------------|-------------|------------|------------|-------------|
| Smoking | | | | | | | | | | | | |
| Never | 4491312 (48.1) | 28132 (0.63) | 3342 (0.07) | 814 (0.02) | 509 (0.01) | 2795 (0.06) | 4451215 (48.0) | 129583 (2.91) | 1840 (0.04) | 524 (0.01) | 214 (0.00) | 1199 (0.03) |
| Former | 2684880 (28.8) | 15829 (0.59) | 2389 (0.09) | 669 (0.02) | 515 (0.02) | 3652 (0.14) | 2677563 (28.9) | 73998 (2.76) | 1468 (0.05) | 500 (0.02) | 292 (0.01) | 1568 (0.06) |
| Current | 1900976 (20.4) | 6683 (0.35) | 602 (0.03) | 111 (0.01) | 190 (0.01) | 4073 (0.21) | 1866970 (20.1) | 30547 (1.64) | 287 (0.02) | 69 (0.00) | 85 (0.00) | 1613 (0.09) |
| <i>Missing</i> | 257224 (2.8) | 916 (0.36) | 41 (0.02) | 7 (0.00) | REDACTED | 60 (0.02) | 271171 (2.9) | 7565 (2.79) | 21 (0.01) | 9 (0.00) | 0 (0.00) | 29 (0.01) |
| Ethnicity | | | | | | | | | | | | |
| White | 7734228 (82.9) | 35276 (0.46) | 4120 (0.05) | 1002 (0.01) | 827 (0.01) | 9604 (0.12) | 7666700 (82.7) | 190672 (2.49) | 2470 (0.03) | 731 (0.01) | 471 (0.01) | 4002 (0.05) |
| Mixed | 160065 (1.7) | 1052 (0.66) | 161 (0.10) | 46 (0.03) | 28 (0.02) | 95 (0.06) | 160932 (1.7) | 4026 (2.50) | 66 (0.04) | 24 (0.01) | 6 (0.00) | 43 (0.03) |
| South Asian | 836666 (9.0) | 11067 (1.32) | 1291 (0.15) | 328 (0.04) | 220 (0.03) | 484 (0.06) | 835735 (9.0) | 34963 (4.18) | 789 (0.09) | 262 (0.03) | 93 (0.01) | 203 (0.02) |
| Black | 309079 (3.3) | 2656 (0.86) | 525 (0.17) | 148 (0.05) | 103 (0.03) | 281 (0.09) | 309730 (3.3) | 7029 (2.27) | 184 (0.06) | 52 (0.02) | 17 (0.01) | 110 (0.04) |
| Other | 294354 (3.2) | 1509 (0.51) | 277 (0.09) | 77 (0.03) | 41 (0.01) | 116 (0.04) | 293822 (3.2) | 5003 (1.70) | 107 (0.04) | 33 (0.01) | REDACTED | 51 (0.02) |
| IMD quintile | | | | | | | | | | | | |
| 1 (least deprived) | 1724481 (18.5) | 7391 (0.43) | 854 (0.05) | 197 (0.01) | 121 (0.01) | 1343 (0.08) | 1741677 (18.8) | 41659 (2.39) | 437 (0.03) | 123 (0.01) | 52 (0.00) | 602 (0.03) |
| 2 | 1850024 (19.8) | 8627 (0.47) | 1021 (0.06) | 260 (0.01) | 177 (0.01) | 1666 (0.09) | 1837273 (19.8) | 43514 (2.37) | 494 (0.03) | 155 (0.01) | 72 (0.00) | 734 (0.04) |
| 3 | 1942791 (20.8) | 9870 (0.51) | 1161 (0.06) | 313 (0.02) | 227 (0.01) | 1975 (0.10) | 1898184 (20.5) | 45357 (2.39) | 574 (0.03) | 179 (0.01) | 86 (0.00) | 830 (0.04) |
| 4 | 2010621 (21.5) | 12239 (0.61) | 1577 (0.08) | 406 (0.02) | 351 (0.02) | 2486 (0.12) | 1994633 (21.5) | 54108 (2.71) | 832 (0.04) | 252 (0.01) | 141 (0.01) | 1026 (0.05) |
| 5 (most deprived) | 1806475 (19.4) | 13433 (0.74) | 1761 (0.10) | 425 (0.02) | 343 (0.02) | 3110 (0.17) | 1795152 (19.4) | 57055 (3.18) | 1279 (0.07) | 393 (0.02) | 240 (0.01) | 1217 (0.07) |
| Total number adults in household | | | | | | | | | | | | |
| 1 | 2260091 (24.2) | 10670 (0.47) | 1459 (0.06) | 346 (0.02) | 339 (0.01) | 3912 (0.17) | 2223814 (24.0) | 49780 (2.24) | 775 (0.03) | 209 (0.01) | 166 (0.01) | 1497 (0.07) |
| 2 | 3850961 (41.3) | 20288 (0.53) | 2319 (0.06) | 564 (0.01) | 392 (0.01) | 3836 (0.10) | 3772870 (40.7) | 94536 (2.51) | 1280 (0.03) | 399 (0.01) | 201 (0.01) | 1686 (0.04) |
| ≥3 | 3223340 (34.5) | 20602 (0.64) | 2596 (0.08) | 691 (0.02) | 488 (0.02) | 2832 (0.09) | 3270235 (35.3) | 97377 (2.98) | 1561 (0.05) | 494 (0.02) | 224 (0.01) | 1226 (0.04) |
| Blood pressure | | | | | | | | | | | | |
| Normal | 2475941 (26.5) | 13741 (0.55) | 1232 (0.05) | 218 (0.01) | 235 (0.01) | 2506 (0.10) | 2452608 (26.5) | 68001 (2.77) | 663 (0.03) | 142 (0.01) | 84 (0.00) | 1020 (0.04) |
| Elevated | 1347313 (14.4) | 7493 (0.56) | 777 (0.06) | 183 (0.01) | 145 (0.01) | 1371 (0.10) | 1335410 (14.4) | 36135 (2.71) | 526 (0.04) | 143 (0.01) | 85 (0.01) | 557 (0.04) |
| High Stage 1 | 2935415 (31.4) | 17396 (0.59) | 2418 (0.08) | 642 (0.02) | 449 (0.02) | 3403 (0.12) | 2924903 (31.6) | 77834 (2.66) | 1382 (0.05) | 443 (0.02) | 227 (0.01) | 1489 (0.05) |

| | | | | | | | | | | | | |
|--|----------------|--------------|-------------|-------------|------------|-------------|----------------|---------------|-------------|------------|------------|-------------|
| High Stage 2 | 1585467 (17.0) | 9740 (0.61) | 1787 (0.11) | 517 (0.03) | 374 (0.02) | 3075 (0.19) | 1552001 (16.7) | 38762 (2.50) | 952 (0.06) | 352 (0.02) | 190 (0.01) | 1267 (0.08) |
| Missing | 990256 (10.6) | 3190 (0.32) | 160 (0.02) | 41 (0.00) | 16 (0.00) | 225 (0.02) | 1001997 (10.8) | 20961 (2.09) | 93 (0.01) | 22 (0.00) | REDACTED | 76 (0.01) |
| High bp or diagnosed hypertension | 2221567 (23.8) | 14915 (0.67) | 3087 (0.14) | 908 (0.04) | 735 (0.03) | 5194 (0.23) | 2174941 (23.5) | 55350 (2.54) | 1634 (0.08) | 611 (0.03) | 341 (0.02) | 2216 (0.10) |
| <i>Comorbidities</i> | | | | | | | | | | | | |
| Chronic respiratory disease ex asthma | 196442 (2.1) | 1706 (0.87) | 602 (0.31) | 152 (0.08) | 177 (0.09) | 1821 (0.93) | 185356 (2.0) | 4401 (2.37) | 412 (0.22) | 145 (0.08) | 114 (0.06) | 766 (0.41) |
| Asthma | 1607197 (17.2) | 9659 (0.60) | 1430 (0.09) | 325 (0.02) | 243 (0.02) | 1974 (0.12) | 1595772 (17.2) | 45694 (2.86) | 906 (0.06) | 249 (0.02) | 130 (0.01) | 792 (0.05) |
| Chronic cardiac disease | 274825 (2.9) | 2446 (0.89) | 758 (0.28) | 191 (0.07) | 238 (0.09) | 1825 (0.66) | 260386 (2.8) | 7115 (2.73) | 396 (0.15) | 133 (0.05) | 130 (0.05) | 811 (0.31) |
| Diabetes | | | | | | | | | | | | |
| No diabetes | 8877057 (95.1) | 46639 (0.53) | 4892 (0.06) | 1131 (0.01) | 793 (0.01) | 8504 (0.10) | 881895 (95.1) | 227899 (2.59) | 2783 (0.03) | 778 (0.01) | 387 (0.00) | 3468 (0.04) |
| Type 1, controlled | 13036 (0.1) | 82 (0.63) | 21 (0.16) | 7 (0.05) | 6 (0.05) | 68 (0.52) | 13740 (0.1) | 336 (2.45) | REDACTED | REDACTED | REDACTED | 29 (0.21) |
| Type 1, uncontrolled | 39054 (0.4) | 313 (0.80) | 78 (0.20) | 23 (0.06) | 21 (0.05) | 191 (0.49) | 38109 (0.4) | 1042 (2.73) | 32 (0.08) | 15 (0.04) | 6 (0.02) | 86 (0.23) |
| Type 2, controlled | 224926 (2.4) | 2300 (1.02) | 650 (0.29) | 193 (0.09) | 178 (0.08) | 913 (0.41) | 221590 (2.4) | 6556 (2.96) | 371 (0.17) | 127 (0.06) | 92 (0.04) | 438 (0.20) |
| Type 2, uncontrolled | 175978 (1.9) | 2187 (1.24) | 722 (0.41) | 240 (0.14) | 214 (0.12) | 877 (0.50) | 177484 (1.9) | 5752 (3.24) | 419 (0.24) | 173 (0.10) | 101 (0.06) | 374 (0.21) |
| Diabetes, no HbA1c | 4341 (0.0) | 39 (0.90) | 11 (0.25) | 7 (0.16) | 7 (0.16) | 27 (0.62) | 4101 (0.0) | 108 (2.63) | 6 (0.15) | 7 (0.17) | 2 (0.05) | 14 (0.34) |
| Haematological cancer | | | | | | | | | | | | |
| Diagnosed < 1 year ago | 2427 (0.0) | 46 (1.90) | 11 (0.45) | REDACTED | 7 (0.29) | 80 (3.30) | 2232 (0.0) | 57 (2.55) | 7 (0.31) | REDACTED | REDACTED | 31 (1.39) |
| Diagnosed 1-4.9 years ago | 7583 (0.1) | 103 (1.36) | 45 (0.59) | 9 (0.12) | 15 (0.20) | 113 (1.49) | 7103 (0.1) | 171 (2.41) | 14 (0.20) | 8 (0.11) | 9 (0.13) | 23 (0.32) |
| Diagnosed ≥5 years ago | 19774 (0.2) | 140 (0.71) | 40 (0.20) | 15 (0.08) | 14 (0.07) | 106 (0.54) | 19067 (0.2) | 462 (2.42) | 23 (0.12) | 9 (0.05) | 14 (0.07) | 51 (0.27) |
| Non-haematological cancer | | | | | | | | | | | | |
| Diagnosed < 1 year ago | 22851 (0.2) | 210 (0.92) | 57 (0.25) | 7 (0.03) | 32 (0.14) | 1248 (5.46) | 20699 (0.2) | 477 (2.30) | 28 (0.14) | 9 (0.04) | 17 (0.08) | 426 (2.06) |

| | | | | | | | | | | | | |
|--|----------------|--------------|-------------|------------|------------|-------------|----------------|--------------|-------------|------------|------------|-------------|
| Diagnosed 1-4.9 years ago | 66072 (0.7) | 434 (0.66) | 106 (0.16) | 19 (0.03) | 48 (0.07) | 1340 (2.03) | 61958 (0.7) | 1488 (2.40) | 51 (0.08) | 16 (0.03) | 24 (0.04) | 496 (0.80) |
| Diagnosed ≥5 years ago | 116131 (1.2) | 715 (0.62) | 138 (0.12) | 21 (0.02) | 49 (0.04) | 757 (0.65) | 110193 (1.2) | 2569 (2.33) | 74 (0.07) | 21 (0.02) | 22 (0.02) | 320 (0.29) |
| Reduced kidney function | | | | | | | | | | | | |
| Estimated GFR 30-60 | 96030 (1.0) | 858 (0.89) | 291 (0.30) | 90 (0.09) | 128 (0.13) | 690 (0.72) | 95475 (1.0) | 2312 (2.42) | 130 (0.14) | 62 (0.06) | 52 (0.05) | 302 (0.32) |
| Estimated GFR <30 | 9342 (0.1) | 352 (3.77) | 140 (1.50) | 37 (0.40) | 67 (0.72) | 322 (3.45) | 9104 (0.1) | 360 (3.95) | 55 (0.60) | 26 (0.29) | 21 (0.23) | 135 (1.48) |
| End-stage renal disease* | 11510 (0.1) | 374 (3.25) | 157 (1.36) | 49 (0.43) | 50 (0.43) | 195 (1.69) | 10787 (0.1) | 396 (3.67) | 56 (0.52) | 30 (0.28) | 18 (0.17) | 90 (0.83) |
| Chronic Liver disease | 54410 (0.6) | 557 (1.02) | 156 (0.29) | 25 (0.05) | 65 (0.12) | 1005 (1.85) | 51834 (0.6) | 1202 (2.32) | 50 (0.10) | 15 (0.03) | 34 (0.07) | 458 (0.88) |
| Stroke/dementia | 76724 (0.8) | 768 (1.00) | 246 (0.32) | 64 (0.08) | 91 (0.12) | 731 (0.95) | 72174 (0.8) | 1762 (2.44) | 103 (0.14) | 32 (0.04) | 39 (0.05) | 321 (0.44) |
| Other neurological disease | 66083 (0.7) | 486 (0.74) | 165 (0.25) | 20 (0.03) | 66 (0.10) | 416 (0.63) | 64030 (0.7) | 1372 (2.14) | 74 (0.12) | 10 (0.02) | 23 (0.04) | 177 (0.28) |
| Solid organ transplant** | 2210 (0.0) | 37 (1.67) | 11 (0.50) | REDACTED | REDACTED | 31 (1.40) | 2122 (0.0) | 64 (3.02) | 8 (0.38) | REDACTED | REDACTED | 9 (0.42) |
| Asplenia | 11363 (0.1) | 107 (0.94) | 22 (0.19) | 10 (0.09) | REDACTED | 89 (0.78) | 10883 (0.1) | 247 (2.27) | 13 (0.12) | REDACTED | REDACTED | 43 (0.40) |
| Rheumatoid/Lupus/ Psoriasis | 421447 (4.5) | 2603 (0.62) | 452 (0.11) | 120 (0.03) | 98 (0.02) | 799 (0.19) | 412685 (4.5) | 11255 (2.73) | 255 (0.06) | 80 (0.02) | 60 (0.01) | 363 (0.09) |
| Other immunosuppressive condition | 33165 (0.4) | 365 (1.10) | 47 (0.14) | 18 (0.05) | 21 (0.06) | 156 (0.47) | 33238 (0.4) | 799 (2.40) | 11 (0.03) | REDACTED | 9 (0.03) | 57 (0.17) |
| Shielding*** | 1976741 (21.2) | 12740 (0.64) | 2284 (0.12) | 548 (0.03) | 532 (0.03) | 6589 (0.33) | 1944911 (21.0) | 53970 (2.77) | 1399 (0.07) | 429 (0.02) | 290 (0.01) | 2922 (0.15) |

*End-stage renal disease includes on dialysis or having had a kidney transplant

**All solid organ transplants, excluding kidney

***Shielding includes organ transplant recipients, renal replacement therapy, haematological cancers, non-haematological cancers, immunodeficiencies/asplenia and severe respiratory conditions.

Table A4. Source of diagnoses for the outcome of SARS-CoV-2 infection by wave and exposure status

| | % of infections that came from each source | |
|-------------------------|--|--------------------------|
| | Living with children | Not living with children |
| Wave 1 | | |
| SGSS test positive | 30 | 32 |
| PCR positive test code | 51 | 45 |
| Sequelae code | 1 | 1 |
| Clinical diagnosis code | 18 | 22 |
| Wave 2 | | |
| SGSS test positive | 25 | 25 |
| PCR positive test code | 73 | 73 |
| Sequelae code | 1 | 1 |
| Clinical diagnosis code | 2 | 2 |

Note: Due to the way OpenSAFELY data is extracted and analysed we are not able to provide the exact information for the cohorts used (for example, if a patient has subsequently changed GP practice and moved to a non-TPP surgery, for information governance reasons their data is no longer available). However, we have analysed this information from what is currently held on the server for the same time periods and these will be very similar to the cohorts in our analysis.

Table A5. Cohort description by outcomes (evidence of SARS-CoV-2 infection recorded in primary care, COVID-19 outcomes and non-COVID 19 deaths) for adults >65 years in wave 1 and wave 2 of the UK pandemic

| | Wave 1 (1st February to 31st August 2020) | | | | | | Wave 2 (1st February to 31st August 2020) | | | | | |
|--------------------------|---|-------------------------------|------------------------------|-------------------------|-----------------|----------------------|---|-------------------------------|------------------------------|-------------------------|-----------------|----------------------|
| | N (column %) | Number (%) within stratum | | | | | N (column %) | Number (%) within stratum | | | | |
| | | Recorded SARS-CoV-2 infection | COVID-19 hospital admissions | COVID-19 ICU admissions | COVID-19 deaths | Non- COVID-19 deaths | | Recorded SARS-CoV-2 infection | COVID-19 hospital admissions | COVID-19 ICU admissions | COVID-19 deaths | Non- COVID-19 deaths |
| Total | 2684524 (100.0) | 18893 (0.70) | 8560 (0.32) | 732 (0.03) | 6507 (0.24) | 45940 (1.71) | 2706505 (100.0) | 34519 (1.28) | 4280 (0.16) | 784 (0.03) | 4108 (0.15) | 21796 (0.81) |
| Age | | | | | | | | | | | | |
| >65-70 | 633913 (23.6) | 2723 (0.43) | 1045 (0.16) | 240 (0.04) | 475 (0.07) | 3682 (0.58) | 632027 (23.4) | 8124 (1.29) | 573 (0.09) | 213 (0.03) | 286 (0.05) | 1654 (0.26) |
| 70-80 | 1357522 (50.6) | 7153 (0.53) | 3239 (0.24) | 428 (0.03) | 2032 (0.15) | 14970 (1.10) | 1375657 (50.8) | 14938 (1.09) | 1809 (0.13) | 459 (0.03) | 1275 (0.09) | 7153 (0.52) |
| 80+ | 693089 (25.8) | 9017 (1.30) | 4276 (0.62) | 64 (0.01) | 4000 (0.58) | 27288 (3.94) | 698821 (25.8) | 11457 (1.64) | 1898 (0.27) | 112 (0.02) | 2547 (0.36) | 12989 (1.86) |
| Sex | | | | | | | | | | | | |
| Female | 1445097 (53.8) | 9065 (0.63) | 3593 (0.25) | 210 (0.01) | 2688 (0.19) | 22087 (1.53) | 1457578 (53.9) | 17650 (1.21) | 1858 (0.13) | 232 (0.02) | 1666 (0.11) | 10433 (0.72) |
| Male | 1239427 (46.2) | 9828 (0.79) | 4967 (0.40) | 522 (0.04) | 3819 (0.31) | 23853 (1.92) | 1248927 (46.1) | 16869 (1.35) | 2422 (0.19) | 552 (0.04) | 2442 (0.20) | 11363 (0.91) |
| BMI (kg/m2) | | | | | | | | | | | | |
| <18.5 | 48518 (1.8) | 710 (1.46) | 263 (0.54) | REDACTED | 253 (0.52) | 2985 (6.15) | 44591 (1.6) | 709 (1.59) | 98 (0.22) | REDACTED | 146 (0.33) | 1395 (3.13) |
| 18.5-24.9 | 800412 (29.8) | 5697 (0.71) | 2405 (0.30) | 122 (0.02) | 1996 (0.25) | 17122 (2.14) | 793996 (29.3) | 8798 (1.11) | 994 (0.13) | 98 (0.01) | 1178 (0.15) | 7870 (0.99) |
| 25-29.9 | 987076 (36.8) | 6129 (0.62) | 2764 (0.28) | 280 (0.03) | 1952 (0.20) | 13160 (1.33) | 994595 (36.7) | 12485 (1.26) | 1401 (0.14) | 280 (0.03) | 1265 (0.13) | 6496 (0.65) |
| 30-34.9 (Obese class I) | 479258 (17.9) | 3500 (0.73) | 1695 (0.35) | 188 (0.04) | 1190 (0.25) | 6105 (1.27) | 485856 (18.0) | 7227 (1.49) | 1002 (0.21) | 228 (0.05) | 803 (0.17) | 2942 (0.61) |
| 35-39.9 (Obese class II) | 156751 (5.8) | 1349 (0.86) | 704 (0.45) | 81 (0.05) | 488 (0.31) | 2259 (1.44) | 159518 (5.9) | 2601 (1.63) | 407 (0.26) | 93 (0.06) | 314 (0.20) | 1030 (0.65) |
| ≥40 (Obese class III) | 61135 (2.3) | 605 (0.99) | 304 (0.50) | 23 (0.04) | 218 (0.36) | 1011 (1.65) | 62493 (2.3) | 1128 (1.81) | 190 (0.30) | 49 (0.08) | 171 (0.27) | 512 (0.82) |
| <i>Missing</i> | 151374 (5.6) | 903 (0.60) | 425 (0.28) | 34 (0.02) | 410 (0.27) | 3298 (2.18) | 165456 (6.1) | 1571 (0.95) | 188 (0.11) | 34 (0.02) | 231 (0.14) | 1551 (0.94) |
| Smoking | | | | | | | | | | | | |
| Never | 1060734 (39.5) | 6317 (0.60) | 2612 (0.25) | 224 (0.02) | 1906 (0.18) | 13564 (1.28) | 1073743 (39.7) | 12321 (1.15) | 1207 (0.11) | 216 (0.02) | 1122 (0.10) | 6413 (0.60) |
| Former | 1395189 (52.0) | 11234 (0.81) | 5401 (0.39) | 471 (0.03) | 4126 (0.30) | 26874 (1.93) | 1404161 (51.9) | 20122 (1.43) | 2830 (0.20) | 539 (0.04) | 2693 (0.19) | 12819 (0.91) |

| | | | | | | | | | | | | |
|--|----------------|--------------|-------------|------------|-------------|--------------|----------------|--------------|-------------|------------|-------------|--------------|
| Current | 222197 (8.3) | 1312 (0.59) | 537 (0.24) | 33 (0.01) | 464 (0.21) | 5423 (2.44) | 222251 (8.2) | 2043 (0.92) | 239 (0.11) | 28 (0.01) | 287 (0.13) | 2539 (1.14) |
| Missing | 6404 (0.2) | 30 (0.47) | 10 (0.16) | REDACTED | 11 (0.17) | 79 (1.23) | 6350 (0.2) | 33 (0.52) | REDACTED | REDACTED | 6 (0.09) | 25 (0.39) |
| Ethnicity | | | | | | | | | | | | |
| White | 2533944 (94.4) | 16803 (0.66) | 7448 (0.29) | 603 (0.02) | 5796 (0.23) | 43761 (1.73) | 2552971 (94.3) | 31054 (1.22) | 3731 (0.15) | 669 (0.03) | 3701 (0.14) | 20786 (0.81) |
| Mixed | 9970 (0.4) | 94 (0.94) | 51 (0.51) | 8 (0.08) | 35 (0.35) | 133 (1.33) | 10249 (0.4) | 117 (1.14) | 13 (0.13) | REDACTED | 19 (0.19) | 78 (0.76) |
| South Asian | 91000 (3.4) | 1407 (1.55) | 709 (0.78) | 73 (0.08) | 467 (0.51) | 1362 (1.50) | 92732 (3.4) | 2791 (3.01) | 438 (0.47) | 88 (0.09) | 310 (0.33) | 611 (0.66) |
| Black | 27818 (1.0) | 397 (1.43) | 248 (0.89) | 29 (0.10) | 145 (0.52) | 443 (1.59) | 28209 (1.0) | 323 (1.15) | 61 (0.22) | 17 (0.06) | 54 (0.19) | 207 (0.73) |
| Other | 21792 (0.8) | 192 (0.88) | 104 (0.48) | 19 (0.09) | 64 (0.29) | 241 (1.11) | 22344 (0.8) | 234 (1.05) | 37 (0.17) | 8 (0.04) | 24 (0.11) | 114 (0.51) |
| IMD quintile | | | | | | | | | | | | |
| 1 (least deprived) | 651069 (24.3) | 3333 (0.51) | 1385 (0.21) | 143 (0.02) | 1101 (0.17) | 8972 (1.38) | 668867 (24.7) | 6175 (0.92) | 633 (0.09) | 127 (0.02) | 677 (0.10) | 4469 (0.67) |
| 2 | 629037 (23.4) | 3795 (0.60) | 1626 (0.26) | 145 (0.02) | 1299 (0.21) | 9782 (1.56) | 636250 (23.5) | 6674 (1.05) | 693 (0.11) | 118 (0.02) | 709 (0.11) | 4685 (0.74) |
| 3 | 580534 (21.6) | 3797 (0.65) | 1753 (0.30) | 162 (0.03) | 1314 (0.23) | 9752 (1.68) | 574847 (21.2) | 6480 (1.13) | 762 (0.13) | 156 (0.03) | 736 (0.13) | 4588 (0.80) |
| 4 | 477447 (17.8) | 4163 (0.87) | 1948 (0.41) | 161 (0.03) | 1430 (0.30) | 9234 (1.93) | 479967 (17.7) | 7360 (1.53) | 899 (0.19) | 180 (0.04) | 922 (0.19) | 4295 (0.89) |
| 5 (most deprived) | 346437 (12.9) | 3805 (1.10) | 1848 (0.53) | 121 (0.03) | 1363 (0.39) | 8200 (2.37) | 346574 (12.8) | 7830 (2.26) | 1293 (0.37) | 203 (0.06) | 1064 (0.31) | 3759 (1.08) |
| Total number adults in household | | | | | | | | | | | | |
| 1 | 913998 (34.0) | 8180 (0.89) | 3690 (0.40) | 184 (0.02) | 3028 (0.33) | 21246 (2.32) | 921594 (34.1) | 12322 (1.34) | 1680 (0.18) | 239 (0.03) | 1859 (0.20) | 9846 (1.07) |
| 2 | 1384390 (51.6) | 7508 (0.54) | 3421 (0.25) | 388 (0.03) | 2459 (0.18) | 18799 (1.36) | 1390726 (51.4) | 15600 (1.12) | 1813 (0.13) | 378 (0.03) | 1645 (0.12) | 9189 (0.66) |
| ≥3 | 386136 (14.4) | 3205 (0.83) | 1449 (0.38) | 160 (0.04) | 1020 (0.26) | 5895 (1.53) | 394185 (14.6) | 6597 (1.67) | 787 (0.20) | 167 (0.04) | 604 (0.15) | 2761 (0.70) |
| Blood pressure | | | | | | | | | | | | |
| Normal | 309796 (11.5) | 3282 (1.06) | 1522 (0.49) | 84 (0.03) | 1334 (0.43) | 10455 (3.37) | 310503 (11.5) | 4830 (1.56) | 636 (0.20) | 89 (0.03) | 754 (0.24) | 5004 (1.61) |
| Elevated | 417855 (15.6) | 3138 (0.75) | 1485 (0.36) | 114 (0.03) | 1176 (0.28) | 7693 (1.84) | 422947 (15.6) | 5614 (1.33) | 695 (0.16) | 117 (0.03) | 754 (0.18) | 3497 (0.83) |
| High Stage 1 | 990139 (36.9) | 6163 (0.62) | 2814 (0.28) | 264 (0.03) | 1969 (0.20) | 13670 (1.38) | 1011992 (37.4) | 12469 (1.23) | 1508 (0.15) | 308 (0.03) | 1317 (0.13) | 6420 (0.63) |
| High Stage 2 | 952842 (35.5) | 6279 (0.66) | 2727 (0.29) | 265 (0.03) | 2017 (0.21) | 14026 (1.47) | 946777 (35.0) | 11544 (1.22) | 1435 (0.15) | 267 (0.03) | 1275 (0.13) | 6828 (0.72) |
| Missing | 13892 (0.5) | 31 (0.22) | 12 (0.09) | REDACTED | 11 (0.08) | 96 (0.69) | 14286 (0.5) | 62 (0.43) | 6 (0.04) | REDACTED | 8 (0.06) | 47 (0.33) |
| High bp or diagnosed hypertension | 1859250 (69.3) | 14515 (0.78) | 6673 (0.36) | 542 (0.03) | 5111 (0.27) | 35289 (1.90) | 1858019 (68.7) | 25105 (1.35) | 3340 (0.18) | 573 (0.03) | 3254 (0.18) | 16794 (0.90) |

| <i>Comorbidities</i> | | | | | | | | | | | | |
|--|----------------|--------------|-------------|------------|-------------|--------------|----------------|--------------|-------------|------------|-------------|--------------|
| Chronic respiratory disease ex asthma | 334940 (12.5) | 4581 (1.37) | 2339 (0.70) | 134 (0.04) | 1659 (0.50) | 12241 (3.65) | 324691 (12.0) | 6356 (1.96) | 1313 (0.40) | 187 (0.06) | 1189 (0.37) | 5638 (1.74) |
| Asthma | 362235 (13.5) | 3209 (0.89) | 1450 (0.40) | 117 (0.03) | 993 (0.27) | 6166 (1.70) | 366433 (13.5) | 5610 (1.53) | 771 (0.21) | 135 (0.04) | 647 (0.18) | 3016 (0.82) |
| Chronic cardiac disease | 571371 (21.3) | 7262 (1.27) | 3520 (0.62) | 172 (0.03) | 2805 (0.49) | 19427 (3.40) | 551840 (20.4) | 10384 (1.88) | 1735 (0.31) | 235 (0.04) | 1962 (0.36) | 9142 (1.66) |
| Diabetes | | | | | | | | | | | | |
| No diabetes | 2201205 (82.0) | 12799 (0.58) | 5512 (0.25) | 510 (0.02) | 4173 (0.19) | 33039 (1.50) | 2221833 (82.1) | 25566 (1.15) | 2774 (0.12) | 506 (0.02) | 2625 (0.12) | 15723 (0.71) |
| Type 1, controlled | 3563 (0.1) | 50 (1.40) | 26 (0.73) | REDACTED | 20 (0.56) | 125 (3.51) | 3710 (0.1) | 57 (1.54) | 9 (0.24) | REDACTED | 12 (0.32) | 64 (1.73) |
| Type 1, uncontrolled | 7408 (0.3) | 127 (1.71) | 54 (0.73) | REDACTED | 47 (0.63) | 273 (3.69) | 7352 (0.3) | 135 (1.84) | 21 (0.29) | REDACTED | 27 (0.37) | 110 (1.50) |
| Type 2, controlled | 323854 (12.1) | 3770 (1.16) | 1803 (0.56) | 125 (0.04) | 1427 (0.44) | 8447 (2.61) | 323947 (12.0) | 5616 (1.73) | 878 (0.27) | 157 (0.05) | 882 (0.27) | 3963 (1.22) |
| Type 2, uncontrolled | 146537 (5.5) | 2116 (1.44) | 1145 (0.78) | 91 (0.06) | 829 (0.57) | 3990 (2.72) | 147893 (5.5) | 3101 (2.10) | 595 (0.40) | 116 (0.08) | 557 (0.38) | 1897 (1.28) |
| Diabetes, no HbA1c | 1957 (0.1) | 31 (1.58) | 20 (1.02) | REDACTED | 11 (0.56) | 66 (3.37) | 1770 (0.1) | 44 (2.49) | REDACTED | REDACTED | REDACTED | 39 (2.20) |
| Haematological cancer | | | | | | | | | | | | |
| Diagnosed < 1 year ago | 3839 (0.1) | 74 (1.93) | 36 (0.94) | 6 (0.16) | 31 (0.81) | 333 (8.67) | 3499 (0.1) | 53 (1.51) | 9 (0.26) | REDACTED | 10 (0.29) | 132 (3.77) |
| Diagnosed 1-4.9 years ago | 11638 (0.4) | 184 (1.58) | 105 (0.90) | 15 (0.13) | 83 (0.71) | 572 (4.91) | 11138 (0.4) | 191 (1.71) | 37 (0.33) | 6 (0.05) | 43 (0.39) | 265 (2.38) |
| Diagnosed ≥5 years ago | 23786 (0.9) | 308 (1.29) | 134 (0.56) | 8 (0.03) | 109 (0.46) | 871 (3.66) | 23008 (0.9) | 384 (1.67) | 72 (0.31) | 16 (0.07) | 80 (0.35) | 408 (1.77) |
| Non-haematological cancer | | | | | | | | | | | | |
| Diagnosed < 1 year ago | 32334 (1.2) | 425 (1.31) | 202 (0.62) | 7 (0.02) | 181 (0.56) | 3614 (11.18) | 29009 (1.1) | 434 (1.50) | 62 (0.21) | REDACTED | 87 (0.30) | 1199 (4.13) |
| Diagnosed 1-4.9 years ago | 95696 (3.6) | 805 (0.84) | 383 (0.40) | 20 (0.02) | 314 (0.33) | 4205 (4.39) | 92748 (3.4) | 1257 (1.36) | 172 (0.19) | 30 (0.03) | 203 (0.22) | 1749 (1.89) |
| Diagnosed ≥5 years ago | 254667 (9.5) | 2244 (0.88) | 1018 (0.40) | 61 (0.02) | 783 (0.31) | 6780 (2.66) | 248878 (9.2) | 3350 (1.35) | 449 (0.18) | 69 (0.03) | 494 (0.20) | 3131 (1.26) |
| Reduced kidney function | | | | | | | | | | | | |
| Estimated GFR 30-60 | 563148 (21.0) | 6172 (1.10) | 2963 (0.53) | 156 (0.03) | 2552 (0.45) | 16311 (2.90) | 560736 (20.7) | 8830 (1.57) | 1470 (0.26) | 202 (0.04) | 1661 (0.30) | 7765 (1.38) |
| Estimated GFR <30 | 41148 (1.5) | 1218 (2.96) | 640 (1.56) | 17 (0.04) | 597 (1.45) | 3856 (9.37) | 40212 (1.5) | 1143 (2.84) | 237 (0.59) | 24 (0.06) | 413 (1.03) | 1892 (4.71) |
| End-stage renal disease* | 6885 (0.3) | 334 (4.85) | 174 (2.53) | 13 (0.19) | 121 (1.76) | 537 (7.80) | 6285 (0.2) | 213 (3.39) | 37 (0.59) | 10 (0.16) | 43 (0.68) | 244 (3.88) |
| Chronic Liver disease | 26389 (1.0) | 380 (1.44) | 173 (0.66) | 8 (0.03) | 138 (0.52) | 1160 (4.40) | 25834 (1.0) | 503 (1.95) | 77 (0.30) | 13 (0.05) | 89 (0.34) | 586 (2.27) |

| | | | | | | | | | | | | |
|--|---------------|-------------|-------------|------------|-------------|--------------|---------------|--------------|-------------|------------|-------------|--------------|
| Stroke/dementia | 204093 (7.6) | 3502 (1.72) | 1581 (0.77) | 63 (0.03) | 1370 (0.67) | 9118 (4.47) | 191057 (7.1) | 4133 (2.16) | 659 (0.34) | 57 (0.03) | 827 (0.43) | 4167 (2.18) |
| Other neurological disease | 54121 (2.0) | 938 (1.73) | 430 (0.79) | 13 (0.02) | 388 (0.72) | 2253 (4.16) | 51397 (1.9) | 1091 (2.12) | 158 (0.31) | 17 (0.03) | 209 (0.41) | 1063 (2.07) |
| Solid organ transplant** | 872 (0.0) | 21 (2.41) | 8 (0.92) | REDACTED | 7 (0.80) | 35 (4.01) | 852 (0.0) | 15 (1.76) | 6 (0.70) | REDACTED | REDACTED | 16 (1.88) |
| Asplenia | 6733 (0.3) | 80 (1.19) | 34 (0.50) | REDACTED | 17 (0.25) | 205 (3.04) | 6639 (0.2) | 107 (1.61) | 15 (0.23) | REDACTED | 15 (0.23) | 107 (1.61) |
| Rheumatoid/Lupus/ Psoriasis | 208673 (7.8) | 1915 (0.92) | 861 (0.41) | 68 (0.03) | 625 (0.30) | 4222 (2.02) | 208797 (7.7) | 3040 (1.46) | 451 (0.22) | 80 (0.04) | 405 (0.19) | 1956 (0.94) |
| Other immunosuppressive condition | 5397 (0.2) | 77 (1.43) | 34 (0.63) | REDACTED | 29 (0.54) | 221 (4.09) | 5658 (0.2) | 86 (1.52) | 12 (0.21) | REDACTED | 16 (0.28) | 112 (1.98) |
| Shielding*** | 956589 (35.6) | 9662 (1.01) | 4547 (0.48) | 317 (0.03) | 3330 (0.35) | 29076 (3.04) | 941453 (34.8) | 14751 (1.57) | 2320 (0.25) | 359 (0.04) | 2244 (0.24) | 13841 (1.47) |

*End-stage renal disease includes on dialysis or having had a kidney transplant

**All solid organ transplants, excluding kidney

***Shielding includes organ transplant recipients, renal replacement therapy, haematological cancers, non-haematological cancers, immunodeficiencies/asplenia and severe respiratory condition

Table A6. Hazard Ratios (HRs) for outcomes in wave 1 and wave 2 (a) evidence of SARS-CoV-2 infection recorded in primary care, (b) COVID-19 hospital admission, (c) COVID-19 ICU admission, (d) COVID-19 death and (e) non-COVID-19 death, stratified by age.

(a) Recorded SARS-CoV-2 infection

| | Wave 1 - Recorded SARS-CoV-2 infection | | | | | | Wave 2 - Recorded SARS-CoV-2 infection | | | | | |
|--|--|------------------------|---------------------------------|------------------|-------------------------|--------------------------|--|------------------------|---------------------------------|------------------|-------------------------|--------------------------|
| | N | Person years follow-up | Rate (per 100,000 person years) | Age-sex adjusted | + Demographic adjusted* | + Comorbidity adjusted** | N | Person years follow-up | Rate (per 100,000 person years) | Age-sex adjusted | + Demographic adjusted* | + Comorbidity adjusted** |
| Adults 65 years and under | | | | | | | | | | | | |
| None | 30415 | 3363742 | 904.2 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 137612 | 1694805 | 8119.64 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Only children 0-11 years | 10883 | 1104266 | 985.54 | 1.08 (1.05-1.10) | 0.97 (0.95-1.00) | 0.98 (0.96-1.01) | 50293 | 538680 | 9336.35 | 1.11 (1.10-1.12) | 1.06 (1.05-1.07) | 1.06 (1.05-1.08) |
| Only children aged \geq 12 years | 5637 | 500507 | 1126.26 | 1.16 (1.13-1.20) | 1.04 (1.01-1.08) | 1.05 (1.01-1.08) | 30192 | 259848 | 11619.1 | 1.30 (1.28-1.31) | 1.22 (1.20-1.24) | 1.22 (1.20-1.24) |
| Children aged 0-11 and \geq 12 | 4625 | 394047 | 1173.72 | 1.22 (1.17-1.26) | 1.00 (0.96-1.04) | 1.01 (0.97-1.05) | 23596 | 202433 | 11656.2 | 1.33 (1.31-1.36) | 1.25 (1.23-1.27) | 1.25 (1.23-1.27) |
| Number of children aged 0-11 years in household | | | | | | | | | | | | |
| 1 child 0-11 years | 5444 | 553847 | 982.94 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 25061 | 275336 | 9101.98 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| 2 children 0-11 years | 4133 | 427480 | 966.83 | 0.99 (0.95-1.04) | 0.99 (0.94-1.03) | 0.99 (0.95-1.04) | 19433 | 206410 | 9414.75 | 1.05 (1.02-1.07) | 1.04 (1.02-1.06) | 1.04 (1.02-1.06) |
| 3 children 0-11 years | 1077 | 99077 | 1087.03 | 1.09 (1.01-1.17) | 0.95 (0.88-1.02) | 0.95 (0.88-1.02) | 4676 | 46184 | 10124.69 | 1.08 (1.04-1.12) | 1.05 (1.01-1.09) | 1.05 (1.01-1.09) |
| \geq 4 children 0-11 years | 229 | 23861 | 959.72 | 0.94 (0.81-1.08) | 0.75 (0.65-0.87) | 0.76 (0.65-0.88) | 1123 | 10750 | 10446.91 | 1.07 (1.00-1.15) | 1.04 (0.97-1.11) | 1.04 (0.97-1.11) |
| Adults over 65 years | | | | | | | | | | | | |
| None | 18078 | 1483331 | 1218.74 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 32652 | 765224 | 4266.98 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Only Children 0-11 years | 401 | 25307 | 1584.51 | 1.39 (1.25-1.54) | 1.06 (0.95-1.18) | 1.04 (0.93-1.16) | 891 | 12906 | 6903.98 | 1.68 (1.57-1.81) | 1.15 (1.07-1.25) | 1.15 (1.06-1.24) |
| Only children aged \geq 12 years | 232 | 16673 | 1391.44 | 1.15 (1.01-1.32) | 0.93 (0.81-1.06) | 0.92 (0.80-1.06) | 571 | 8707 | 6557.61 | 1.57 (1.44-1.72) | 1.17 (1.07-1.29) | 1.16 (1.06-1.27) |
| Children aged 0-11 and \geq 12 | 182 | 8746 | 2081.06 | 1.72 (1.47-2.00) | 1.19 (1.02-1.39) | 1.17 (1.00-1.37) | 405 | 4607 | 8790.69 | 2.07 (1.86-2.30) | 1.29 (1.15-1.44) | 1.27 (1.14-1.42) |
| Number of children aged 0-11 years in household | | | | | | | | | | | | |
| 1 child 0-11 years | 224 | 14959 | 1497.48 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 467 | 7773 | 6008.26 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| 2 children 0-11 years | 118 | 8061 | 1463.91 | 0.95 (0.75-1.21) | 0.92 (0.72-1.16) | 0.92 (0.72-1.17) | 312 | 4052 | 7699.9 | 1.25 (1.07-1.46) | 1.15 (0.98-1.34) | 1.15 (0.98-1.34) |
| 3 children 0-11 years | 50 | 1909 | 2619.12 | 1.56 (1.13-2.15) | 1.29 (0.93-1.79) | 1.29 (0.93-1.80) | 93 | 906 | 10263.71 | 1.48 (1.17-1.87) | 1.20 (0.94-1.52) | 1.21 (0.95-1.53) |
| \geq 4 children 0-11 years | 9 | 379 | 2372.99 | 1.31 (0.67-2.54) | 1.02 (0.52-2.01) | 1.09 (0.55-2.17) | 19 | 175 | 10865.94 | 1.44 (0.87-2.39) | 1.11 (0.67-1.85) | 1.14 (0.68-1.89) |

*Demographic adjusted model: Adjusted for age, sex, ethnicity, number adults in household, IMD, BMI, smoking.

**Comorbidity-adjusted model: Adjusted for age, sex, ethnicity, number adults in household, IMD, BMI, smoking, hypertension or high blood pressure, chronic respiratory disease, asthma, cancer, chronic liver disease, stroke or dementia, other neurological disease, reduced kidney function, end-stage renal disease, solid organ transplant, asplenia, rheumatoid, lupus or psoriasis, other immunosuppressive condition.

(b) COVID-19 hospital admissions

| | Wave 1 - COVID-19 hospital admissions | | | | | | Wave 2 - COVID-19 hospital admissions | | | | | |
|--|---------------------------------------|---------------------------|------------------------------------|------------------|----------------------------|-----------------------------|---------------------------------------|---------------------------|------------------------------------|------------------|----------------------------|-----------------------------|
| | HR (95% CI) | | | | | | HR (95% CI) | | | | | |
| | N | Person years follow-up | Rate (per 100,000 person years) | Age-sex adjusted | + Demographic adjusted* | + Comorbidity adjusted** | N | Person years follow-up | Rate (per 100,000 person years) | Age-sex adjusted | + Demographic adjusted* | + Comorbidity adjusted** |
| Adults 65 years and under | | | | | | | | | | | | |
| None | 4319 | 3370737 | 128.13 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 2292 | 1426755 | 160.64 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Only children aged 0-11 years | 874 | 1106851 | 78.96 | 1.03 (0.95-1.12) | 0.91 (0.84-0.98) | 0.92 (0.85-1.00) | 553 | 453698 | 121.89 | 1.34 (1.21-1.49) | 1.17 (1.06-1.30) | 1.18 (1.06-1.31) |
| Only children aged ≥ 12 years | 670 | 501807 | 133.52 | 1.17 (1.07-1.28) | 1.05 (0.96-1.14) | 1.06 (0.97-1.16) | 424 | 219433 | 193.23 | 1.41 (1.26-1.57) | 1.25 (1.12-1.39) | 1.26 (1.12-1.40) |
| Children aged 0-11 and ≥12 | 511 | 395082 | 129.34 | 1.39 (1.26-1.53) | 1.09 (0.99-1.20) | 1.12 (1.01-1.23) | 346 | 170861 | 202.5 | 1.85 (1.64-2.08) | 1.42 (1.26-1.61) | 1.44 (1.28-1.63) |
| Number of children aged 0-11 years in household | | | | | | | | | | | | |
| 1 child 0-11 years | 445 | 555137 | 80.16 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 274 | 231874 | 118.17 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| 2 children 0-11 years | 312 | 428486 | 72.81 | 0.98 (0.85-1.14) | 0.98 (0.84-1.14) | 0.99 (0.85-1.15) | 203 | 173826 | 116.78 | 1.08 (0.90-1.30) | 1.10 (0.91-1.32) | 1.10 (0.91-1.33) |
| 3 children 0-11 years | 97 | 99319 | 97.66 | 1.32 (1.06-1.66) | 1.11 (0.88-1.39) | 1.10 (0.88-1.39) | 56 | 38934 | 143.83 | 1.30 (0.98-1.74) | 1.08 (0.81-1.45) | 1.07 (0.80-1.43) |
| ≥4 children 0-11 years | 20 | 23908 | 83.65 | 1.16 (0.74-1.81) | 0.87 (0.55-1.36) | 0.89 (0.56-1.39) | 20 | 9064 | 220.66 | 1.98 (1.25-3.12) | 1.46 (0.92-2.31) | 1.46 (0.93-2.31) |
| Adults over 65 years | | | | | | | | | | | | |
| None | 8172 | 1485541 | 550.1 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 4056 | 640805 | 632.95 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Only children aged 0-11 years | 186 | 25357 | 733.52 | 1.41 (1.21-1.63) | 1.09 (0.93-1.27) | 1.06 (0.91-1.24) | 96 | 10842 | 885.46 | 1.68 (1.37-2.06) | 0.97 (0.79-1.21) | 0.96 (0.77-1.19) |
| Only children aged ≥ 12 years | 119 | 16698 | 712.64 | 1.28 (1.07-1.53) | 1.04 (0.86-1.25) | 1.03 (0.86-1.25) | 69 | 7309 | 944.06 | 1.64 (1.29-2.09) | 1.06 (0.82-1.36) | 1.04 (0.81-1.34) |
| Children aged 0-11 and ≥12 | 83 | 8767 | 946.69 | 1.68 (1.35-2.10) | 1.19 (0.95-1.49) | 1.16 (0.92-1.45) | 56 | 3878 | 1444.22 | 2.47 (1.89-3.24) | 1.23 (0.93-1.62) | 1.19 (0.90-1.58) |
| Number of children aged 0-11 years in household | | | | | | | | | | | | |
| 1 child 0-11 years | 97 | 14988 | 647.18 | 1.00 (. - .) | 1.00 (. - .) | 1.00 (. - .) | 47 | 6522 | 720.64 | 1.00 (. - .) | 1.00 (. - .) | 1.00 (. - .) |
| 2 children 0-11 years | 59 | 8075 | 730.67 | 1.10 (0.79-1.52) | 1.07 (0.77-1.50) | 1.06 (0.75-1.48) | 33 | 3407 | 968.48 | 1.29 (0.83-2.02) | 1.15 (0.73-1.79) | 1.12 (0.71-1.76) |
| 3 children 0-11 years | 27 | 1913 | 1411.24 | 1.93 (1.26-2.94) | 1.64 (1.06-2.53) | 1.61 (1.04-2.49) | 12 | 765 | 1568.59 | 1.78 (0.93-3.41) | 1.32 (0.68-2.54) | 1.37 (0.69-2.71) |
| ≥4 children 0-11 years | REDACT | 381 | 787.34 | 1.01 (0.32-3.19) | 0.82 (0.26-2.61) | 0.81 (0.25-2.64) | REDACTED | 147 | 2712.59 | 2.68 (0.94-7.64) | 1.99 (0.69-5.76) | 2.08 (0.70-6.18) |

*Demographic adjusted model: Adjusted for age, sex, ethnicity, number adults in household, IMD, BMI, smoking.

**Comorbidity-adjusted model: Adjusted for age, sex, ethnicity, number adults in household, IMD, BMI, smoking, hypertension or high blood pressure, chronic respiratory disease, asthma, cancer, chronic liver disease, stroke or dementia, other neurological disease, reduced kidney function, end-stage renal disease, solid organ transplant, asplenia, rheumatoid, lupus or psoriasis, other immunosuppressive condition.

c) COVID-19 ICU admission

| | Wave 1 - COVID-19 ICU admission | | | | | | Wave 2 - COVID-19 ICU admission | | | | | |
|--|---------------------------------|------------------------|--------------------|-------------------|-------------------------|--------------------------|---------------------------------|------------------------|---------------------------------|------------------|-------------------------|--------------------------|
| | HR (95% CI) | | | | | | HR (95% CI) | | | | | |
| | N | Person years follow-up | Rate (per 100,000) | Age-sex adjusted | + Demographic adjusted* | + Comorbidity adjusted** | N | Person years follow-up | Rate (per 100,000 person years) | Age-sex adjusted | + Demographic adjusted* | + Comorbidity adjusted** |
| Adults 65 years and under | | | | | | | | | | | | |
| None | 1133 | 3371778 | 33.6 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 733 | 1710507 | 42.85 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Only children aged 0-11 years | 193 | 1107083 | 17.43 | 1.09 (0.92-1.30) | 0.90 (0.76-1.06) | 0.91 (0.76-1.07) | 160 | 544105 | 29.41 | 1.47 (1.21-1.78) | 1.18 (0.98-1.42) | 1.19 (0.98-1.43) |
| Only children aged ≥ 12 years | 167 | 501982 | 33.27 | 1.21 (1.02-1.44) | 1.04 (0.87-1.23) | 1.05 (0.88-1.24) | 120 | 263187 | 45.6 | 1.35 (1.10-1.64) | 1.13 (0.92-1.38) | 1.13 (0.93-1.39) |
| Children aged 0-11 and ≥12 | 108 | 395222 | 27.33 | 1.36 (1.10-1.67) | 0.98 (0.79-1.21) | 1.00 (0.81-1.23) | 88 | 204948 | 42.94 | 1.72 (1.36-2.17) | 1.20 (0.95-1.53) | 1.22 (0.96-1.55) |
| Number of children aged 0-11 years in household | | | | | | | | | | | | |
| 1 child 0-11 years | 102 | 555254 | 18.37 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 91 | 278056 | 32.73 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| 2 children 0-11 years | 65 | 428570 | 15.17 | 0.96 (0.70-1.31) | 0.96 (0.71-1.31) | 0.97 (0.71-1.32) | 47 | 208489 | 22.54 | 0.77 (0.54-1.10) | 0.77 (0.55-1.09) | 0.77 (0.55-1.10) |
| 3 children 0-11 years | 19 | 99347 | 19.12 | 1.25 (0.76-2.04) | 1.00 (0.60-1.64) | 1.00 (0.61-1.64) | 19 | 46693 | 40.69 | 1.42 (0.86-2.32) | 1.13 (0.69-1.87) | 1.11 (0.67-1.84) |
| ≥4 children 0-11 years | 7 | 23913 | 29.27 | 2.08 (0.97-4.44) | 1.44 (0.67-3.07) | 1.49 (0.70-3.18) | REDACTED | 10868 | 27.6 | 1.00 (0.31-3.19) | 0.69 (0.22-2.20) | 0.69 (0.22-2.19) |
| Adults over 65 years | | | | | | | | | | | | |
| None | 684 | 1487082 | 46 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 727 | 768349 | 94.62 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Only children aged 0-11 years | 25 | 25393 | 98.45 | 1.51 (1.01-2.27) | 1.10 (0.72-1.68) | 1.09 (0.71-1.67) | 28 | 12997 | 215.44 | 1.99 (1.36-2.91) | 1.32 (0.88-1.98) | 1.30 (0.87-1.95) |
| Only children aged ≥ 12 years | 16 | 16721 | 95.69 | 1.64 (1.00-2.70) | 1.27 (0.76-2.13) | 1.26 (0.75-2.12) | 13 | 8763 | 148.35 | 1.42 (0.82-2.47) | 1.05 (0.59-1.86) | 1.04 (0.59-1.84) |
| Children aged 0-11 and ≥12 | 7 | 8783 | 79.7 | 1.32 (0.63-2.78) | 0.87 (0.41-1.86) | 0.87 (0.41-1.85) | 16 | 4646 | 344.36 | 3.26 (1.98-5.38) | 1.90 (1.13-3.19) | 1.86 (1.11-3.14) |
| Number of children aged 0-11 years in household | | | | | | | | | | | | |
| 1 child 0-11 years | 12 | 15010 | 79.95 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 14 | 7819 | 179.06 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| 2 children 0-11 years | 10 | 8085 | 123.69 | 1.50 (0.65-3.46) | 1.37 (0.60-3.14) | 1.47 (0.64-3.36) | 8 | 4085 | 195.85 | 1.08 (0.45-2.57) | 0.95 (0.40-2.25) | 0.95 (0.41-2.21) |
| 3 children 0-11 years | REDACTED | 1917 | 104.34 | 1.19 (0.27-5.27) | 0.93 (0.20-4.47) | 0.90 (0.19-4.29) | 6 | 917 | 654.44 | 3.18 (1.24-8.15) | 2.28 (0.91-5.71) | 2.49 (0.99-6.24) |
| ≥4 children 0-11 years | REDACTED | 381 | 262.13 | 3.13 (0.39-25.01) | 2.38 (0.29-19.30) | 2.31 (0.27-20.12) | 0 | 177 | 0 | 0.00 (- -) | 0.00 (0.00-0.00) | 0.00 (0.00-0.00) |

*Demographic adjusted model: Adjusted for age, sex, ethnicity, number adults in household, IMD, BMI, smoking.

**Comorbidity-adjusted model: Adjusted for age, sex, ethnicity, number adults in household, IMD, BMI, smoking, hypertension or high blood pressure, chronic respiratory disease, asthma, cancer, chronic liver disease, stroke or dementia, other neurological disease, reduced kidney function, end-stage renal disease, solid organ transplant, asplenia, rheumatoid, lupus or psoriasis, other immunosuppressive condition.

d) COVID-19 death

| | Wave 1 - COVID-19 death | | | | | | Wave 2 - COVID-19 death | | | | | |
|--|-------------------------|------------------------|---------------------------------|------------------|-------------------------|--------------------------|-------------------------|------------------------|---------------------------------|-------------------|-------------------------|--------------------------|
| | N | Person years follow-up | Rate (per 100,000 person years) | HR (95% CI) | | | N | Person years follow-up | Rate (per 100,000 person years) | HR (95% CI) | | |
| | | | | Age-sex adjusted | + Demographic adjusted* | + Comorbidity adjusted** | | | | Age-sex adjusted | + Demographic adjusted* | + Comorbidity adjusted** |
| Adults 65 years and under | | | | | | | | | | | | |
| None | 990 | 3372068 | 29.36 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 492 | 1710567 | 28.76 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Only children aged 0-11 years | 92 | 1107136 | 8.31 | 0.81 (0.64-1.03) | 0.71 (0.56-0.89) | 0.71 (0.57-0.90) | 28 | 544119 | 5.15 | 0.59 (0.39-0.89) | 0.52 (0.35-0.78) | 0.52 (0.35-0.78) |
| Only children aged \geq 12 years | 90 | 502029 | 17.93 | 0.91 (0.73-1.14) | 0.85 (0.68-1.07) | 0.87 (0.69-1.09) | 48 | 263197 | 18.24 | 0.99 (0.73-1.36) | 0.97 (0.70-1.32) | 0.97 (0.71-1.33) |
| Children aged 0-11 and \geq 12 | 47 | 395252 | 11.89 | 0.92 (0.67-1.25) | 0.73 (0.54-0.99) | 0.76 (0.56-1.03) | 23 | 204956 | 11.22 | 1.00 (0.64-1.54) | 0.82 (0.53-1.27) | 0.84 (0.54-1.30) |
| Number of children aged 0-11 years in household | | | | | | | | | | | | |
| 1 child 0-11 years | 58 | 555281 | 10.45 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 16 | 278063 | 5.75 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| 2 children 0-11 years | 26 | 428589 | 6.07 | 0.73 (0.45-1.17) | 0.74 (0.47-1.19) | 0.74 (0.47-1.18) | 8 | 208493 | 3.84 | 0.89 (0.37-2.12) | 0.91 (0.39-2.12) | 0.92 (0.40-2.12) |
| 3 children 0-11 years | 6 | 99352 | 6.04 | 0.73 (0.31-1.70) | 0.60 (0.25-1.43) | 0.59 (0.25-1.40) | REDACTED | 46694 | 6.42 | 1.51 (0.43-5.26) | 1.32 (0.37-4.73) | 1.10 (0.30-4.06) |
| \geq 4 children 0-11 years | REDACTED | 23915 | 8.36 | 1.09 (0.26-4.51) | 0.80 (0.19-3.31) | 0.83 (0.20-3.46) | REDACTED | 10868 | 9.2 | 2.32 (0.29-18.36) | 1.80 (0.21-15.28) | 1.74 (0.19-16.06) |
| Adults over 65 years | | | | | | | | | | | | |
| None | 6294 | 1487196 | 423.21 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 3934 | 768392 | 511.98 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Only children aged 0-11 years | 101 | 25396 | 397.7 | 1.18 (0.97-1.44) | 0.88 (0.71-1.08) | 0.86 (0.70-1.06) | 72 | 12999 | 553.89 | 1.63 (1.29-2.06) | 1.11 (0.87-1.41) | 1.09 (0.86-1.40) |
| Only children aged \geq 12 years | 66 | 16723 | 394.66 | 1.03 (0.81-1.32) | 0.81 (0.63-1.04) | 0.80 (0.62-1.03) | 56 | 8764 | 638.98 | 1.59 (1.22-2.07) | 1.17 (0.89-1.54) | 1.14 (0.86-1.50) |
| Children aged 0-11 and \geq 12 | 46 | 8784 | 523.67 | 1.40 (1.05-1.88) | 0.94 (0.70-1.27) | 0.92 (0.68-1.24) | 46 | 4647 | 989.84 | 2.52 (1.88-3.37) | 1.48 (1.09-2.02) | 1.44 (1.05-1.97) |
| Number of children aged 0-11 years in household | | | | | | | | | | | | |
| 1 child 0-11 years | 56 | 15012 | 373.05 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 31 | 7820 | 396.44 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| 2 children 0-11 years | 29 | 8086 | 358.65 | 0.94 (0.60-1.47) | 0.90 (0.58-1.42) | 0.90 (0.57-1.42) | 32 | 4085 | 783.3 | 1.92 (1.18-3.15) | 1.72 (1.06-2.81) | 1.75 (1.07-2.87) |
| 3 children 0-11 years | 13 | 1917 | 678.18 | 1.54 (0.84-2.83) | 1.24 (0.67-2.31) | 1.26 (0.68-2.34) | 6 | 917 | 654.14 | 1.37 (0.57-3.31) | 0.92 (0.38-2.22) | 0.92 (0.37-2.27) |
| \geq 4 children 0-11 years | REDACTED | 382 | 786.3 | 1.56 (0.50-4.87) | 1.20 (0.37-3.91) | 1.10 (0.33-3.65) | REDACTED | 177 | 1697.05 | 3.08 (0.91-10.40) | 1.85 (0.53-6.49) | 2.08 (0.57-7.56) |

*Demographic adjusted model: Adjusted for age, sex, ethnicity, number adults in household, IMD, BMI, smoking.

**Comorbidity-adjusted model: Adjusted for age, sex, ethnicity, number adults in household, IMD, BMI, smoking, hypertension or high blood pressure, chronic respiratory disease, asthma, cancer, chronic liver disease, stroke or dementia, other neurological disease, reduced kidney function, end-stage renal disease, solid organ transplant, asplenia, rheumatoid, lupus or psoriasis, other immunosuppressive condition.

e) non-COVID-19 deaths

| | Wave 1 - non-COVID-19 deaths | | | | | | Wave 2 - non-COVID-19 deaths | | | | | |
|--|------------------------------|------------------------|---------------------------------|------------------|-------------------------|--------------------------|------------------------------|------------------------|---------------------------------|------------------|-------------------------|--------------------------|
| | N | Person years follow-up | Rate (per 100,000 person years) | HR (95% CI) | | | N | Person years follow-up | Rate (per 100,000 person years) | HR (95% CI) | | |
| | | | | Age-sex adjusted | + Demographic adjusted* | + Comorbidity adjusted** | | | | Age-sex adjusted | + Demographic adjusted* | + Comorbidity adjusted** |
| Adults 65 years and under | | | | | | | | | | | | |
| None | 9033 | 3372068 | 267.88 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 3746 | 1710567 | 218.99 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Only children aged 0-11 years | 666 | 1107136 | 60.16 | 0.50 (0.46-0.55) | 0.61 (0.56-0.66) | 0.62 (0.57-0.68) | 259 | 544119 | 47.6 | 0.55 (0.48-0.63) | 0.64 (0.56-0.74) | 0.66 (0.57-0.75) |
| Only children aged ≥ 12 years | 597 | 502029 | 118.92 | 0.59 (0.54-0.64) | 0.72 (0.66-0.78) | 0.73 (0.67-0.80) | 264 | 263197 | 100.3 | 0.63 (0.55-0.71) | 0.74 (0.65-0.84) | 0.76 (0.67-0.87) |
| Children aged 0-11 and ≥12 | 284 | 395252 | 71.85 | 0.49 (0.43-0.55) | 0.58 (0.51-0.66) | 0.61 (0.54-0.69) | 140 | 204956 | 68.31 | 0.63 (0.53-0.75) | 0.73 (0.61-0.87) | 0.77 (0.64-0.91) |
| Number of children aged 0-11 years in household | | | | | | | | | | | | |
| 1 child 0-11 years | 391 | 555281 | 70.41 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 152 | 278063 | 54.66 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| 2 children 0-11 years | 222 | 428589 | 51.8 | 0.90 (0.77-1.07) | 0.96 (0.81-1.14) | 1.00 (0.84-1.18) | 83 | 208493 | 39.81 | 0.85 (0.65-1.11) | 0.89 (0.68-1.16) | 0.91 (0.69-1.19) |
| 3 children 0-11 years | 47 | 99352 | 47.31 | 0.88 (0.65-1.20) | 0.90 (0.66-1.22) | 1.00 (0.73-1.36) | 20 | 46694 | 42.83 | 0.97 (0.61-1.55) | 0.97 (0.61-1.56) | 1.07 (0.67-1.72) |
| ≥4 children 0-11 years | 6 | 23915 | 25.09 | 0.51 (0.23-1.15) | 0.48 (0.22-1.08) | 0.57 (0.26-1.27) | REDACTED | 10868 | 36.8 | 0.92 (0.34-2.49) | 0.86 (0.31-2.37) | 1.03 (0.37-2.84) |
| Adults over 65 years | | | | | | | | | | | | |
| None | 44787 | 1487196 | 3011.51 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 21283 | 768392 | 2769.81 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Only children aged 0-11 years | 541 | 25396 | 2130.27 | 1.03 (0.95-1.13) | 0.98 (0.90-1.08) | 0.98 (0.89-1.07) | 230 | 12999 | 1769.38 | 0.95 (0.84-1.09) | 0.91 (0.79-1.04) | 0.91 (0.80-1.04) |
| Only children aged ≥ 12 years | 404 | 16723 | 2415.79 | 1.00 (0.91-1.11) | 0.96 (0.87-1.06) | 0.97 (0.87-1.07) | 181 | 8764 | 2065.27 | 0.94 (0.81-1.09) | 0.90 (0.78-1.05) | 0.90 (0.77-1.04) |
| Children aged 0-11 and ≥12 | 208 | 8784 | 2367.92 | 1.05 (0.91-1.20) | 1.00 (0.87-1.15) | 1.01 (0.88-1.16) | 102 | 4647 | 2194.86 | 1.08 (0.89-1.31) | 1.03 (0.84-1.25) | 1.05 (0.86-1.28) |
| Number of children aged 0-11 years in household | | | | | | | | | | | | |
| 1 child 0-11 years | 320 | 15012 | 2131.69 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 142 | 7820 | 1815.94 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| 2 children 0-11 years | 161 | 8086 | 1991.15 | 0.95 (0.79-1.15) | 0.99 (0.82-1.20) | 1.02 (0.84-1.24) | 65 | 4085 | 1591.09 | 0.90 (0.67-1.21) | 0.91 (0.68-1.22) | 0.95 (0.71-1.28) |
| 3 children 0-11 years | 53 | 1917 | 2764.89 | 1.26 (0.94-1.70) | 1.29 (0.95-1.73) | 1.26 (0.93-1.71) | 17 | 917 | 1853.39 | 1.00 (0.60-1.66) | 1.01 (0.60-1.69) | 1.02 (0.61-1.72) |
| ≥4 children 0-11 years | 7 | 382 | 1834.69 | 0.76 (0.36-1.63) | 0.76 (0.35-1.61) | 0.83 (0.38-1.79) | 6 | 177 | 3394.1 | 1.73 (0.76-3.92) | 1.75 (0.76-4.02) | 1.98 (0.84-4.65) |

*Demographic adjusted model: Adjusted for age, sex, ethnicity, number adults in household, IMD, BMI, smoking.

**Comorbidity-adjusted model: Adjusted for age, sex, ethnicity, number adults in household, IMD, BMI, smoking, hypertension or high blood pressure, chronic respiratory disease, asthma, cancer, chronic liver disease, stroke or dementia, other neurological disease, reduced kidney function, end-stage renal disease, solid organ transplant, asplenia, rheumatoid, lupus or psoriasis, other immunosuppressive condition.

Table A7. Hazard Ratios (HRs) for threadworm between 2018 to 2019, stratified by age

| | | | | Worms HR (95% CI) | | |
|--|----------|--------------|-------|-------------------|-------------------------|--------------------------|
| | N | Person years | Rate | Age-sex adjusted | + Demographic adjusted* | + Comorbidity adjusted** |
| Adults 65 years and under | | | | | | |
| None | 470 | 5712919 | 8.23 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Only children aged 0-11 years | 508 | 1818356 | 27.94 | 2.73 (2.36-3.16) | 2.70 (2.33-3.13) | 2.70 (2.33-3.12) |
| Only children aged ≤ 12 years | 84 | 782920 | 10.73 | 1.29 (1.01-1.64) | 1.31 (1.03-1.68) | 1.30 (1.02-1.67) |
| Children aged 0-11 and >12 years | 120 | 605682 | 19.81 | 2.13 (1.70-2.67) | 2.07 (1.65-2.61) | 2.08 (1.65-2.62) |
| Number of children aged 1-<11 years in household | | | | | | |
| 1 child 0-11 years | 180 | 905723 | 19.87 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| 2 children 0-11 years | 219 | 708900 | 30.89 | 1.58 (1.28-1.96) | 1.58 (1.28-1.96) | 1.59 (1.28-1.97) |
| 3 children 0-11 years | 71 | 164533 | 43.15 | 2.14 (1.60-2.87) | 2.10 (1.57-2.82) | 2.14 (1.59-2.87) |
| ≤4 children 0-11 years | 38 | 39199 | 96.94 | 4.64 (3.12-6.91) | 4.48 (2.99-6.69) | 4.30 (2.87-6.45) |
| Adults over 65 years | | | | | | |
| None | 82 | 2256656 | 3.63 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Only children aged 0-11 years | 6 | 34074 | 17.61 | 4.51 (1.66-12.25) | 4.13 (1.32-12.99) | 2.98 (0.69-12.87) |
| Only children aged ≤ 12 years | REDACTED | 23454 | 8.53 | 2.27 (0.57-9.05) | 2.15 (0.48-9.65) | 1.13 (0.13-9.58) |
| Children aged 0-11 and >12 years | REDACTED | 11741 | 8.52 | 2.17 (0.30-15.63) | 1.89 (0.23-15.66) | 1.99 (0.23-17.19) |
| Number of children aged 1-<11 years in household | | | | | | |
| 1 child 0-11 years | REDACTED | 20038 | 9.98 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| 2 children 0-11 years | REDACTED | 10951 | 27.4 | 3.02 (0.38-24.08) | 2.93 (0.33-25.81) | 0.79 (0.06-10.22) |
| 3 children 0-11 years | REDACTED | 2561 | 39.04 | 4.45 (0.28-69.99) | 4.85 (0.27-87.30) | 0.00 (0.00-0.00) |
| ≤4 children 0-11 years | 0 | 524 | 0 | 0.00 (- -) | 0.00 (- -) | 0.00 (0.00-0.00) |

*Demographic adjusted model: Adjusted for age, sex, ethnicity, number adults in household, IMD, BMI, smoking.

**Comorbidity-adjusted model: Adjusted for age, sex, ethnicity, number adults in household, IMD, BMI, smoking, hypertension or high blood pressure, chronic respiratory disease, asthma, cancer, chronic liver disease, stroke or dementia, other neurological disease, reduced kidney function, end-stage renal disease, solid organ transplant, asplenia, rheumatoid, lupus or psoriasis, other immunosuppressive condition.

Table A8: Hazard Ratios (HRs) and 95% confidence intervals (CIs) for COVID-19 outcomes among those ≤65 years, comparing results of complete case analysis with multiple imputation to account for ethnicity.

| | Evidence of SARS-CoV-2 infection in primary care | | Hospital admission | | ICU admission | | Death from COVID-19 | |
|----------------------------------|--|---------------------|--------------------|---------------------|------------------|---------------------|---------------------|---------------------|
| | Complete case* | Multiple imputation | Complete case* | Multiple imputation | Complete case* | Multiple imputation | Complete case* | Multiple imputation |
| WAVE 1 | | | | | | | | |
| None | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Only children aged 0-11 years | 0.98 (0.96-1.01) | 1.01 (0.98-1.03) | 0.92 (0.85-1.00) | 0.95 (0.88-1.02) | 0.91 (0.76-1.07) | 0.97 (0.83-1.14) | 0.71 (0.57-0.90) | 0.73 (0.59-0.90) |
| Only children aged ≥ 12 years | 1.05 (1.01-1.08) | 1.07 (1.04-1.10) | 1.06 (0.97-1.16) | 1.07 (0.99-1.16) | 1.05 (0.88-1.24) | 1.11 (0.95-1.29) | 0.87 (0.69-1.09) | 0.92 (0.75-1.12) |
| Children aged 0-11 and ≥12 years | 1.01 (0.97-1.05) | 1.04 (1.00-1.07) | 1.12 (1.01-1.23) | 1.14 (1.04-1.24) | 1.00 (0.81-1.23) | 1.06 (0.88-1.29) | 0.76 (0.56-1.03) | 0.79 (0.60-1.04) |
| WAVE 2 | | | | | | | | |
| None | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Only children aged 0-11 years | 1.06 (1.05-1.08) | 1.06 (1.05-1.08) | 1.18 (1.06-1.31) | 1.23 (1.12-1.36) | 1.19 (0.98-1.43) | 1.22 (1.02-1.45) | 0.52 (0.35-0.78) | 0.62 (0.44-0.87) |
| Only children aged ≥ 12 years | 1.22 (1.20-1.24) | 1.25 (1.23-1.27) | 1.26 (1.12-1.40) | 1.31 (1.19-1.45) | 1.13 (0.93-1.39) | 1.26 (1.05-1.51) | 0.97 (0.71-1.33) | 0.92 (0.69-1.22) |
| Children aged 0-11 and ≥12 years | 1.25 (1.23-1.27) | 1.25 (1.24-1.27) | 1.44 (1.28-1.63) | 1.55 (1.39-1.73) | 1.22 (0.96-1.55) | 1.31 (1.05-1.62) | 0.84 (0.54-1.30) | 0.89 (0.60-1.32) |

*Comorbidity-adjusted model: Adjusted for age, sex, ethnicity, number adults in household, IMD, BMI, smoking, hypertension or high blood pressure, chronic respiratory disease, asthma, cancer, chronic liver disease, stroke or dementia, other neurological disease, reduced kidney function, end-stage renal disease, solid organ transplant, asplenia, rheumatoid, lupus or psoriasis, other immunosuppressive condition.

Table A9: Hazard Ratios (HRs) and 95% confidence intervals (CIs) for COVID-19 outcomes among those >65 years, comparing results of complete case analysis with multiple imputation to account for ethnicity

| | Evidence of SARS-CoV-2 infection in primary care | | Hospital admission | | ICU admission | | Death from COVID-19 | |
|--|--|---------------------|--------------------|---------------------|------------------|---------------------|---------------------|---------------------|
| | Complete case* | Multiple imputation | Complete case* | Multiple imputation | Complete case* | Multiple imputation | Complete case* | Multiple imputation |
| WAVE 1 | | | | | | | | |
| None | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Only children aged 0-11 years | 1.04 (0.93-1.16) | 1.09 (0.99-1.20) | 1.06 (0.91-1.24) | 1.10 (0.96-1.26) | 1.09 (0.71-1.67) | 1.07 (0.72-1.58) | 0.86 (0.70-1.06) | 0.86 (0.72-1.04) |
| Only children aged \geq 12 years | 0.92 (0.80-1.06) | 0.98 (0.86-1.10) | 1.03 (0.86-1.25) | 1.03 (0.87-1.22) | 1.26 (0.75-2.12) | 1.24 (0.77-1.99) | 0.80 (0.62-1.03) | 0.82 (0.72-1.04) |
| Children aged 0-11 and \geq 12 years | 1.17 (1.00-1.37) | 1.19 (1.02-1.37) | 1.16 (0.92-1.45) | 1.15 (0.93-1.42) | 0.87 (0.41-1.85) | 0.91 (0.45-1.84) | 0.92 (0.68-1.24) | 0.93 (0.70-1.23) |
| WAVE 2 | | | | | | | | |
| None | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Only children aged 0-11 years | 1.15 (1.06-1.24) | 1.28 (1.19-1.37) | 0.96 (0.77-1.19) | 1.09 (0.90-1.32) | 1.30 (0.87-1.95) | 1.38 (0.97-1.99) | 1.09 (0.86-1.40) | 1.13 (0.91-1.41) |
| Only children aged \geq 12 years | 1.16 (1.06-1.27) | 1.28 (1.17-1.39) | 1.04 (0.81-1.34) | 1.17 (0.93-1.47) | 1.04 (0.59-1.84) | 0.97 (0.57-1.67) | 1.14 (0.86-1.50) | 1.15 (0.90-1.48) |
| Children aged 0-11 and \geq 12 years | 1.27 (1.14-1.42) | 1.45 (1.31-1.61) | 1.19 (0.90-1.58) | 1.48 (1.16-1.90) | 1.86 (1.11-3.14) | 2.18 (1.38-3.44) | 1.44 (1.05-1.97) | 1.59 (1.20-2.10) |

*Comorbidity-adjusted model: Adjusted for age, sex, ethnicity, number adults in household, IMD, BMI, smoking, hypertension or high blood pressure, chronic respiratory disease, asthma, cancer, chronic liver disease, stroke or dementia, other neurological disease, reduced kidney function, end-stage renal disease, solid organ transplant, asplenia, rheumatoid, lupus or psoriasis, other immunosuppressive condition.

Table A10: Bias-adjusted hazard ratios accounting for high-risk occupation for the association between living in a household with children and Covid-19 outcome among adults aged ≤ 65 years assuming a hazard ratio between high-risk occupation and outcome of 1.3

| Outcome | Exposure | Wave | Main analysis hazard ratio (95% CI) | Bias-adjusted hazard ratio (95% CI) |
|-------------------------------|----------------------------------|--------|-------------------------------------|-------------------------------------|
| Reported SARS-CoV-2 infection | Only children aged 0-11 years | Wave 1 | 0.98 (0.96-1.01) | 0.95 (0.93-0.98) |
| | | Wave 2 | 1.06 (1.05-1.08) | 1.03 (1.02-1.05) |
| | Only children aged ≥12 years | Wave 1 | 1.05 (1.01-1.08) | 1.02 (0.98-1.05) |
| | | Wave 2 | 1.22 (1.20-1.24) | 1.19 (1.17-1.21) |
| | Children aged 0-11 and ≥12 years | Wave 1 | 1.01 (0.97-1.05) | 0.98 (0.94-1.02) |
| | | Wave 2 | 1.25 (1.23-1.27) | 1.22 (1.20-1.24) |
| COVID-19 hospital admission | Only children aged 0-11 years | Wave 1 | 0.92 (0.85-1.00) | 0.90 (0.83-0.97) |
| | | Wave 2 | 1.18 (1.06-1.31) | 1.15 (1.03-1.27) |
| | Only children aged ≥12 years | Wave 1 | 1.06 (0.97-1.16) | 1.03 (0.94-1.13) |
| | | Wave 2 | 1.26 (1.12-1.40) | 1.23 (1.09-1.36) |
| | Children aged 0-11 and ≥12 years | Wave 1 | 1.12 (1.01-1.23) | 1.09 (0.98-1.20) |
| | | Wave 2 | 1.44 (1.28-1.63) | 1.40 (1.25-1.59) |
| COVID-19 ICU admission | Only children aged 0-11 years | Wave 1 | 0.91 (0.76-1.07) | 0.89 (0.74-1.04) |
| | | Wave 2 | 1.19 (0.98-1.43) | 1.16 (0.95-1.39) |
| | Only children aged ≥12 years | Wave 1 | 1.05 (0.88-1.24) | 1.02 (0.86-1.21) |
| | | Wave 2 | 1.13 (0.93-1.39) | 1.10 (0.90-1.35) |
| | Children aged 0-11 and ≥12 years | Wave 1 | 1.00 (0.81-1.23) | 0.97 (0.79-1.20) |
| | | Wave 2 | 1.22 (0.96-1.55) | 1.19 (0.93-1.51) |
| COVID-19 death | Only children aged 0-11 years | Wave 1 | 0.71 (0.57-0.90) | 0.69 (0.55-0.88) |
| | | Wave 2 | 0.52 (0.35-0.78) | 0.51 (0.34-0.76) |
| | Only children aged ≥12 years | Wave 1 | 0.87 (0.69-1.09) | 0.85 (0.67-1.06) |
| | | Wave 2 | 0.97 (0.71-1.33) | 0.94 (0.69-1.29) |
| | Children aged 0-11 and ≥12 years | Wave 1 | 0.76 (0.56-1.03) | 0.74 (0.54-1.00) |
| | | Wave 2 | 0.84 (0.54-1.30) | 0.82 (0.53-1.26) |

Table A11: Bias-adjusted hazard ratios accounting for high-risk occupation for the association between living in a household with children and Covid-19 outcomes among adults aged ≤ 65 years assuming a hazard ratio between high-risk occupation and outcome of 2

| Outcome | Exposure | Wave | Main analysis hazard ratio (95% CI) | Bias-adjusted hazard ratio (95% CI) |
|-------------------------------|--|--------|-------------------------------------|-------------------------------------|
| Reported SARS-CoV-2 infection | Only children aged 0-11 years | Wave 1 | 0.98 (0.96-1.01) | 0.91 (0.89-0.94) |
| | | Wave 2 | 1.06 (1.05-1.08) | 0.98 (0.97-1.00) |
| | Only children aged ≥ 12 years | Wave 1 | 1.05 (1.01-1.08) | 0.97 (0.94-1.00) |
| | | Wave 2 | 1.22 (1.20-1.24) | 1.13 (1.11-1.15) |
| | Children aged 0-11 and ≥ 12 years | Wave 1 | 1.01 (0.97-1.05) | 0.94 (0.90-0.97) |
| | | Wave 2 | 1.25 (1.23-1.27) | 1.16 (1.14-1.18) |
| COVID-19 hospital admission | Only children aged 0-11 years | Wave 1 | 0.92 (0.85-1.00) | 0.85 (0.79-0.93) |
| | | Wave 2 | 1.18 (1.06-1.31) | 1.09 (0.98-1.21) |
| | Only children aged ≥ 12 years | Wave 1 | 1.06 (0.97-1.16) | 0.98 (0.90-1.07) |
| | | Wave 2 | 1.26 (1.12-1.40) | 1.17 (1.04-1.30) |
| | Children aged 0-11 and ≥ 12 years | Wave 1 | 1.12 (1.01-1.23) | 1.04 (0.94-1.14) |
| | | Wave 2 | 1.44 (1.28-1.63) | 1.33 (1.19-1.51) |
| COVID-19 ICU admission | Only children aged 0-11 years | Wave 1 | 0.91 (0.76-1.07) | 0.84 (0.70-0.99) |
| | | Wave 2 | 1.19 (0.98-1.43) | 1.10 (0.91-1.32) |
| | Only children aged ≥ 12 years | Wave 1 | 1.05 (0.88-1.24) | 0.97 (0.81-1.15) |
| | | Wave 2 | 1.13 (0.93-1.39) | 1.05 (0.86-1.29) |
| | Children aged 0-11 and ≥ 12 years | Wave 1 | 1.00 (0.81-1.23) | 0.93 (0.75-1.14) |
| | | Wave 2 | 1.22 (0.96-1.55) | 1.13 (0.89-1.44) |
| COVID-19 death | Only children aged 0-11 years | Wave 1 | 0.71 (0.57-0.90) | 0.66 (0.53-0.83) |
| | | Wave 2 | 0.52 (0.35-0.78) | 0.48 (0.32-0.72) |
| | Only children aged ≥ 12 years | Wave 1 | 0.87 (0.69-1.09) | 0.81 (0.64-1.01) |
| | | Wave 2 | 0.97 (0.71-1.33) | 0.90 (0.66-1.23) |
| | Children aged 0-11 and ≥ 12 years | Wave 1 | 0.76 (0.56-1.03) | 0.70 (0.52-0.95) |
| | | Wave 2 | 0.84 (0.54-1.30) | 0.78 (0.50-1.20) |

Table A12: Bias-adjusted hazard ratios accounting for high-risk occupation for the association between living in a household with children and Covid-19 outcomes among adults aged ≤ 65 years assuming a hazard ratio between high-risk occupation and outcome of 3

| Outcome | Exposure | Wave | Main analysis Hazard ratio (95% CI) | Bias-adjusted hazard ratio (95% CI) |
|-------------------------------|--|--------|-------------------------------------|-------------------------------------|
| Reported SARS-CoV-2 infection | Only children aged 0-11 years | Wave 1 | 0.98 (0.96-1.01) | 0.86 (0.85-0.89) |
| | | Wave 2 | 1.06 (1.05-1.08) | 0.94 (0.93-0.95) |
| | Only children aged ≥ 12 years | Wave 1 | 1.05 (1.01-1.08) | 0.93 (0.89-0.95) |
| | | Wave 2 | 1.22 (1.20-1.24) | 1.08 (1.06-1.09) |
| | Children aged 0-11 and ≥ 12 years | Wave 1 | 1.01 (0.97-1.05) | 0.89 (0.86-0.93) |
| | | Wave 2 | 1.25 (1.23-1.27) | 1.10 (1.09-1.12) |
| COVID-19 hospital admission | Only children aged 0-11 years | Wave 1 | 0.92 (0.85-1.00) | 0.81 (0.75-0.88) |
| | | Wave 2 | 1.18 (1.06-1.31) | 1.04 (0.94-1.16) |
| | Only children aged ≥ 12 years | Wave 1 | 1.06 (0.97-1.16) | 0.94 (0.86-1.02) |
| | | Wave 2 | 1.26 (1.12-1.40) | 1.11 (0.99-1.24) |
| | Children aged 0-11 and ≥ 12 years | Wave 1 | 1.12 (1.01-1.23) | 0.99 (0.89-1.09) |
| | | Wave 2 | 1.44 (1.28-1.63) | 1.27 (1.13-1.44) |
| COVID-19 ICU admission | Only children aged 0-11 years | Wave 1 | 0.91 (0.76-1.07) | 0.80 (0.67-0.94) |
| | | Wave 2 | 1.19 (0.98-1.43) | 1.05 (0.86-1.26) |
| | Only children aged ≥ 12 years | Wave 1 | 1.05 (0.88-1.24) | 0.93 (0.78-1.09) |
| | | Wave 2 | 1.13 (0.93-1.39) | 1.00 (0.82-1.23) |
| | Children aged 0-11 and ≥ 12 years | Wave 1 | 1.00 (0.81-1.23) | 0.88 (0.71-1.09) |
| | | Wave 2 | 1.22 (0.96-1.55) | 1.08 (0.85-1.37) |
| COVID-19 death | Only children aged 0-11 years | Wave 1 | 0.71 (0.57-0.90) | 0.63 (0.50-0.79) |
| | | Wave 2 | 0.52 (0.35-0.78) | 0.46 (0.31-0.69) |
| | Only children aged ≥ 12 years | Wave 1 | 0.87 (0.69-1.09) | 0.77 (0.61-0.96) |
| | | Wave 2 | 0.97 (0.71-1.33) | 0.86 (0.63-1.17) |
| | Children aged 0-11 and ≥ 12 years | Wave 1 | 0.76 (0.56-1.03) | 0.67 (0.49-0.91) |
| | | Wave 2 | 0.84 (0.54-1.30) | 0.74 (0.48-1.15) |

Supplementary methods

Algorithm to identify households in TPP, using addresses registered in patient record

1) Get all address details for fully registered patients

- Find all permanent patient addresses that were active on 01 Feb 2020 or recorded since
- Combine the house name/number, remove punctuation (commas, full stops, apostrophes), double spaces and leading/trailing whitespace from house name/number and road
- Replace street, lane etc with the abbreviation (street -> St, lane -> Ln, place -> Pl, avenue -> Ave, road -> Rd, close -> Cl, drive -> Dr)
- Find registrations for patients that were active on or since 01 Feb 2020 (making sure the patient was alive on 01 Feb 2020)

- Filter the patient addresses based on those registrations

2) Build an Address table using the distinct address fields

- For each distinct (house name/number + road + post code), assign a unique Address_ID

3) Set the Address_ID on each individual patient address

- Join to Address table from 2) on house name/number + road + post code

4) End addresses that started before the property was sold

- Import land registry property sales data (www.gov.uk/government/statistical-data-sets/price-paid-data-downloads)
- Apply the same processing as 1) to the address fields
- Set address IDs on the land registry house sales data using the same Address table from 2) joining on house name/number + road + post code
- End all patient addresses at properties where the patient address start date was before the property was sold (under the assumption that in the majority of cases that means the occupants moved out)
- If a patient address has an unset start date (imported data), use the registration start date for this step

5) Get the latest "active" patient address per patient

- Filter to those which were active on 01 Feb 2020 or recorded since (need to do this again now we've ended some based on property sales)
- Filter to the latest per patient

6) Create the HouseholdMember table

- Insert a row for each patient address from 5), using the Address_ID as the Household_ID (one household per address)

7) Create the Household table

- Select the distinct Address_IDs as the Household_ID into the Household table (one household per address)
- Set the size based on the number of members
- Use the PotentialCareHomeAddress table to set the CareHome flag
- Check the address fields to identify NFA / Unknown addresses (e.g. postcode "ZZ99 ...", house name "NFA", road "Unknown", ...)

Table of primary care codes used as evidence of SARS-CoV-2 infection in primary care with links to codelists

| Evidence | Link to OpenSAFELY codelists |
|-----------------------------------|---|
| Clinical diagnosis of COVID-19 | https://codelists.opensafely.org/codelist/opensafely/covid-identification-in-primary-care-probable-covid-clinical-code/2020-07-16/ |
| Positive swab test for SARS-CoV-2 | https://codelists.opensafely.org/codelist/opensafely/covid-identification-in-primary-care-probable-covid-positive-test/2020-07-16/ |
| Sequelae of COVID-19 | https://codelists.opensafely.org/codelist/opensafely/covid-identification-in-primary-care-probable-covid-sequelae/2020-07-16/ |

Table of covariate definitions

| Covariate | Link to OpenSAFELY codelists |
|---|---|
| Obesity | Body mass index (BMI) was ascertained within the 10 years prior to 1 Feb 2020 and recorded when the patient was over 16 years old. Grouped using categories derived from the World Health Organisation classification of BMI: no evidence of obesity <30 kg/m ² ; obese I 30-34.9; obese II 35-39.9; obese III 40+ |
| Smoking | Grouped into current, former and never smokers. |
| Ethnicity | Categorised as a five-level variable, White, Mixed, South Asian, Black or Other |
| Age | age groups were: 18-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80+ years. |
| Total number of adults in the household | Categorised as 1, 2, and 3 or more. |
| Region | We used the Sustainability and Transformation Partnership area (STP, an NHS administrative grouping) of the patient's general practice as a marker of region. |
| Shielding patients | Identified at study start as having one or more of (ever); organ transplant, renal replacement therapy, haematological cancers, non-haematological cancers, immunodeficiencies/asplenia and chronic respiratory disease. |

Table of chronic comorbidities with details and links to codelists

| Comorbidity | Details | Link to OpenSAFELY codelists | Time frame codes searched |
|-----------------------------|---|---|--|
| Asthma | Asthma code AND no codes indicating chronic obstructive pulmonary disease | https://codelists.opensafely.org/codelist/opensafely/asthma-diagnosis/2020-04-15/ | Ever diagnosed prior to study start date |
| Chronic Respiratory Disease | Including chronic obstructive pulmonary disease, fibrosing lung disease, bronchiectasis or cystic fibrosis | https://codelists.opensafely.org/codelist/opensafely/chronic-respiratory-disease/2020-04-10/ | Ever diagnosed prior to study start date |
| Chronic heart disease | Including chronic heart failure, ischaemic heart disease, and severe valve or congenital heart disease likely to require lifelong follow-up | https://codelists.opensafely.org/codelist/opensafely/chronic-cardiac-disease-snomed/2020-04-08-draft/ | Ever diagnosed prior to study start date |
| Diabetes mellitus | Defined using a combination of diabetes diagnosis codes, anti-diabetes drugs and HBA1C records were used to define diabetes status. | https://codelists.opensafely.org/codelist/opensafely/diabetes-unknown-type/2020-06-29/ https://codelists.opensafely.org/codelist/opensafely/type-1-diabetes/2020-06-29/ https://codelists.opensafely.org/codelist/opensafely/type-2-diabetes/2020-06-29/ https://codelists.opensafely.org/codelist/opensafely/antidiabetic-drugs/2020-07-16/ https://codelists.opensafely.org/codelist/opensafely/insulin-medication/2020-04-26/ | Ever diagnosed prior to study start date |
| Chronic liver disease | Including all chronic viral hepatitis disease, signs of cirrhosis such as oesophageal varices and liver transplant (recipient only) | https://codelists.opensafely.org/codelist/opensafely/chronic-liver-disease/2020-06-02/ | Ever diagnosed prior to study start date |
| Stroke/dementia | Diagnosis of stroke or dementia. | https://codelists.opensafely.org/codelist/opensafely/stroke-updated/2020-06-02/ https://codelists.opensafely.org/codelist/opensafely/dementia/2020-04-22/ | Ever diagnosed prior to study start date |

| | | | |
|--|--|---|--|
| Other chronic neurological diseases | Including conditions in which respiratory function may be compromised, such as motor neurone disease, myasthenia gravis, multiple sclerosis, Parkinson's disease, cerebral palsy, quadriplegia or hemiplegia and progressive cerebellar disease. | https://codelists.opensafely.org/codelist/opensafely/other-neurological-conditions/2020-06-02/ | Ever diagnosed prior to study start date |
| Common autoimmune diseases | Rheumatoid Arthritis, Systemic Lupus Erythematosus or psoriasis | https://codelists.opensafely.org/codelist/opensafely/ra-sle-psoriasis/2020-04-14/ | Ever diagnosed prior to study start date |
| Solid organ transplant | Codes indicating other organ transplant (kidney is grouped with renal replacement therapy below) | https://codelists.opensafely.org/codelist/opensafely/other-organ-transplant/2020-07-15/ | Ever diagnosed prior to study start date |
| Asplenia | Including splenectomy or a spleen dysfunction, including sickle cell disease. | https://codelists.opensafely.org/codelist/opensafely/asplenia/2020-06-02/ | Ever diagnosed prior to study start date |
| Immunosuppression (including permanent immunodeficiency such as HIV, sickle cell disease, other immunosuppressive conditions and temporary immunodeficiency) | Other immunosuppressive conditions included human immunodeficiency virus or a condition inducing permanent immunodeficiency ever diagnosed, or aplastic anaemia or temporary immunodeficiency recorded within the last year. | https://codelists.opensafely.org/codelist/opensafely/hiv/2020-07-13/ https://codelists.opensafely.org/codelist/opensafely/permanent-immunosuppression/2020-06-02/ https://codelists.opensafely.org/codelist/opensafely/sickle-cell-disease/2020-04-14/ https://codelists.opensafely.org/codelist/opensafely/temporary-immunosuppression/2020-04-24/ https://codelists.opensafely.org/codelist/opensafely/aplastic-anaemia/2020-04-24/ | Ever diagnosed prior to study start date |
| Cancer (haematological or non haematological) | | https://codelists.opensafely.org/codelist/opensafely/haematological-cancer/2020-04-15/ https://codelists.opensafely.org/codelist/opensafely/cancer-excluding-lung-and-haematological/2020-04-15/ https://codelists.opensafely.org/codelist/opensafely/lung-cancer/2020-04-15/ | Cancer was grouped by time since the first diagnosis (within the last year; between 1 and 4.9 years ago; more than 5 years ago). |

| | | | |
|--|---|--|--|
| Estimated GFR (eGFR) | Kidney function was ascertained from the most recent serum creatinine measurement, and was converted into eGFR using the CKD-EPI equation, with reduced kidney function grouped into eGFR 30–59.9 or <30 ml/min/1.73m ² . No serum creatinine measurement was categorized as eGFR>60mls.min/1.73m ² | | Ever record prior to study start date |
| *End-stage renal disease includes | On dialysis or having had a kidney transplant ever. | https://codelists.opensafely.org/codelist/opensafely/dialysis/2020-07-16/ https://codelists.opensafely.org/codelist/opensafely/kidney-transplant/2020-07-15/ | Ever diagnosis prior to study start date |
| High blood pressure or diagnosis of hypertension | A previous coded diagnosis of hypertension or the most recent recording indicating systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg | https://codelists.opensafely.org/codelist/opensafely/hypertension/2020-04-28/ | Ever diagnosis or record prior to study start date |

Further details of quantitative bias analysis

We used literature estimates to specify a plausible range of values for the association between COVID-19 and high-risk occupation.

In data from the Labour Force Survey 31% of UK working-age adults with children were key workers, whereas 27% of those without children were key workers. Key workers¹⁶ are workers who are deemed by the UK government to be essential during the COVID-19 outbreak. This grouping includes health care workers, social care workers, and others in frontline positions (i.e. police), who, as such, are likely at higher risk of COVID-19 infection.

Based on this literature we estimated the prevalence of high-risk occupation among those with and without children as 0.35 and 0.25 respectively.

We also specified a range of plausible values for the association between high-risk occupation and SARS-CoV-2 infection. Among key workers, it would be anticipated that healthcare workers are at highest risk. As such we used the risk ratio between health care worker occupation and COVID-19 seroprevalence in a published Danish study (1.33, 95% CI 1.12-1.58)(Iversen et al. 2020)¹⁷ and also the risk ratio for COVID-19 related admission to hospital between patient facing and non-patient facing healthcare workers (hazard ratio 3.30, 2.13 to 5.13)(Shah et al. 2020) to specify a range of plausible values for the association between high-risk occupation and COVID-19 infection: 1.3, 2 and 3.

We assume the effect of high-risk occupation on COVID-19 outcomes is mediated solely by risk of SARS-CoV-2 infection. In UK Office for National Statistics data there was no difference in COVID-19 mortality between health care workers and the working-age population.(Office for National Statistics 2020)

References

- Iversen, Kasper, Henning Bundgaard, Rasmus B. Hasselbalch, Jonas H. Kristensen, Pernille B. Nielsen, Mia Pries-Heje, Andreas D. Knudsen, et al. 2020. "Risk of COVID-19 in Health-Care Workers in Denmark: An Observational Cohort Study." *The Lancet Infectious Diseases*, August. [https://doi.org/10.1016/S1473-3099\(20\)30589-2](https://doi.org/10.1016/S1473-3099(20)30589-2).
- Office for National Statistics. 2020. "Coronavirus (COVID-19) Related Deaths by Occupation, England and Wales: Deaths Registered between 9 March and 28 December 2020." *Ons.Gov.Uk*. January 25, 2020. <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/causesofdeath/bulletins/coronaviruscovid19relateddeathsbyoccupationenglandandwales/deathsregisteredbetween9marchand28december2020#related-links>.
- Shah, Anoop S. V., Rachael Wood, Ciara Gribben, David Caldwell, Jennifer Bishop, Amanda Weir, Sharon Kennedy, et al. 2020. "Risk of Hospital Admission with Coronavirus Disease 2019 in Healthcare Workers and Their Households: Nationwide Linkage Cohort Study." *BMJ* 371 (October): m3582.